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iAbstract
Insulin resistance is a disease state characterised by the reduced ability of
insulin to exert its effects in peripheral tissues, skeletal muscle and adipose
tissue. This condition has been associated with a number of other disease
states including obesity and hypertension.
The hypertensive Milan rat has previously been shown to be insulin
resistant. Unlike any other hypertensive, insulin resistant model, the Milan
rat has a normotensive, isogenic control which responds normally to
insulin. As GLUT-4,the insulin-stimulated glucose transporter, had been
implicated in insulin resistance I examined the levels of GLUT-4present in
the Milan rat. Results suggest that the insulin resistance experienced by this
hypertensive strain may be due to a reduction in GLUT-4within the
intracellular membranes of skeletal muscle. This is due to the nature of
insulin-stimulated glucose transport, which arises as a result of GLUT-4
translocatlng to the cell surface from an intracellular pool, and therefore
increasing the rate of glucose uptake. Consequently, any reduction in
intracellular GLUT-4may account for the insulin resistance observed.
Further studies eXamined the stroke-prone spontaneously hypertensive rat,
and the stroke-prone spontaneously hypertensive rat F2 generation. The F2
generation contains individuals that are extremely hypertensive and others
which are normotensive. This was done to determine if the decrease in
GLUT-4observed in the hypertensive Milan rat correlated with increasing
blood pressure. The results suggest that GLUT-4levels in the stroke-prone
spontaneously hypertensive rat are not altered by an increase in blood
pressure. This result is in agreement with most studies on skeletal muscle
GLUT-4,and highlights the complex nature of insulin resistance associated
with hypertension.
The concluding chapter discusses the effects of oestrogen, and derivatives,
on insulin-stimulated glucose uptake in 3T3-Ll adipocytes. Previous studies
have shown that females taking steroid hormones, either by means of the
contraceptive pill, of hormone replacement therapy, tend to suffer from
insulin resistance. In 3T3-Ll adipocytesa 48 hour treatment with 30nM
oestrogen significantly reduces insulin-stimulated glucose transport. This
demonstrates that the cells have developed insulin resistance. However,
ii
these cells do not have reduced GLUT-4 levels and the insulin resistance,
induced by oestrogen, occurs by an as yet unknown mechanism.
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1Chapter 1
Introduction
21.1 General introduction: The facilitative glucose
transporter family (GLUTs).
The transport of glucose across the plasma membrane and into the cytosol of a
cell is arguably the most important transport function a cell performs as 0-
glucose is required for cellular growth, homeostasis and metabolism. In 1982
Lienhard and his colleagues purified and partially sequenced the first
member of the family now known as the facilitative glucose transporters, or
GLUTs[Lienhard et al. (1982)]. These transporters allow the movement of
glucose across the plasma membrane down its chemical gradient, either into
or out of cells. Furthermore this family of proteins are specific for the 0-
enantiomer of glucose and are not coupled to any energy-requiring
components, such as ATPhydrolysis or a H+gradient. Initially, GLUT-l was
purified from erythrocytes and antibodies raised against the polypeptide.
Together the antibodies and the partial sequence obtained from the purified
protein assisted in the isolation of eDNAclone in 1985 and subsequently the
isolation of the gene coding for GLUT-1[Fukumoto et al. (1988)]. GLUT-1is
expressed at the highest levels at the blood-brain barrier and erythrocytes,
but it is also found in almost every mammalian cell at low levels. GLUT-1 is
located on the plasma membrane, is not enriched in any intracellular
compartment and is widely regarded as the "house-keeping" glucose
transporter [Flier et al. (1987)].
Subsequent to the isolation of the GLUT-1eDNAmore members of the family
were discovered by screening cDNA libraries' of several tissues with the
GLUT-1 eDNA under conditions of low stringency, thus allowing the
identification of cDNAssimilar to GLUT-I. Using this method, the eDNAfor
GLUT-2was discovered [Thorens et al. (1988); Fukumoto et al. (1988)].
Experimental analysis of this transporter revealed that it is a high-capacity,
3high Km transporter. These properties are ideally suited to allow the liver to
function as one of the key tissues involved in glucose homeostasis; the high
Km and transport capacity endows GLUT-2wnth properties enabling the rapid
efflux of glucose from the liver following gluconeogenesis [Gould et al.
(1991); Thorens er al. (1988)].
GLUT-3, the next isoform identified, was found to be the prominent isoform in
the brain and neural tissue. GLUT-3 is expressed at high levels in human
foetal muscle, but Northern blot analysis of the adult skeletal muscle revealed
no trace of GLUT-3. In contrast high GLUT-3 mRNA is present in a range of
other tissues such as the placenta, liver, heart and kidney. The mRNA for
GLUT-3 has been found at high levels in these tissues, but the sites of protein
expression are more restricted, indicating that perhaps the GLUT-3 may
undergo negative post-translational regulation [Gould & Holman (1993)].
GLUT-S, the major facilitative glucose transporter of the small intestine was
also identified by library screening with the GLUT-1 cDNA probe [Kayano et
al. (1988)]. It is localised to the apical brush border on the luminal side of
absorptive epithelial cells [Davidson et al. (1992)]. This transporter has a
high affinity for fructose and a low affinity for glucose, therefore it seems
reasonable to assume that it plays a major role in the uptake of dietary
fructose [Burant et al. (1992)]. This explanation may be the reason that GLUT-
S is found at lesser levels in many tissues including muscle, brain and adipose
tissue [Shepherd et al. (1992].
Using the same method of library screening another transporter-like
transcript was identified [Kayano et al. (1990)]. The GLUT-6eDNAwas found to
contain multiple stop codons and several frame shifts, and therefore is
unlikely to encode a functional transporter. The eDNA is similar to that of
4GLUT-3and it has been suggested that the glucose transporter-like region of
GLUT-6 may have arisen from the insertion of a reverse transcribed copy of
GLUT-3into a non-coding region of a universally expressed gene [Kayano et
al. (1990)].
GLUT-7was the last known member of the facilitative glucose transporter
family to be discovered [Waddell et al. (1992)]. This transporter is at expressed
at high levels in hepatic microsomes where it is a component of the G-6-Pase
system. It is the least well characterised of all the members of the GLUT
family, and will not be discussed further here. For a summary of the tissue
distribution of the facilitative glucose transporters see table 1.1.
The final member of this family, GLUT4,will be considered in detail below and
is the main isoform studied in this thesis.
1.1.1 Structure and membrane topology of the GLUTs
After the purification and cloning of the GLUTswork began on the analysis
of the predicted amino acid sequences, and modelling of the membrane
topology of the transporters. This work revealed that mammalian glucose
transporters are highly homologous with one another. There is also a high
level of sequence identity between that of the mammalian transporters and
those of other species including Eschericia coli, yeast, algae and protozoa.
This high degree of similarity probably relates to a common mechanism of
transport catalysis, a common type of substrate and is suggestive of a
Table 1.1.
Isoform.
GLUT-l
GLUT-2
GLUT-3
GLUT-4
GLUT-S
GLUT-7
5
Major sites of expression of the different
glucose transporters in human and rodent
tissues.
Tissue.
Placenta; brain; blood-tissue barrier; adipose and
muscle tissue (low levels); tissue culture cells;
transformed cells.
Liver; pancreatic s-cetl: kidney proximal tubule and
small intestine (basolateral membranes).
Brain and nerve cells in rodents.
Brain, nerve; low levels in placenta, liver and heart
(humans).
Muscle, heart and adipose tissue.
Small intestine (apical membranes), kidney, testis,
brain, muscle adipose tissue, muscle and brain at low
levels (humans).
Small intestine (apical membranes), kidney (rat).
Microsomal glucose transporter; liver
6common evolution from a single ancestral gene. The common features
revealed by sequence alignment and analysis of the transporters include 12
predicted amphipathic helices arranged so that both the N-and C-termini are
at the cytoplasmic surface. Also predicted are large loops between helices 1
and 2 and between helices 6 and 7. The loop between helices 6 and 7 divides
the structure into two halves, usually referred to as the N-terminal domain
and the Cvterrninal domain. The loops between the remainder of the helices at
the cytoplasmic surface are very short and the length of these loops (about 8
residues) is a conserved feature of the entire family. The short loops place
severe constraints on the possible tertiary structure and suggest very close
packing of the helices at the inner surface of the membrane in each half of
the protein. The length and sequence identity of the loops at the
extracellular surface of these proteins are very varied but are generally
longer than the loops at the cytoplasmic surface. This may potentially result
in a less compact helical packing at the external surface. The two
dimensional topography, shown in figure 1.1, with the N- and C-termini on
the cytoplasmic surface. This has been examined using anti-peptide
antibodies which react only when the inner surface of the transporter in
exposed, as in inverted vesicles containing human erythrocyte GLUT-I. This
work supports the overall nature of this model. The general features of this
model including the membrane spanning topology have been confirmed by
experimental analysis (reviewed in Gould & Holman (1993)).
1.2 The insulin-stimulated glucose transporter -
GLUT-4.
Fat and muscle are unique tissues with respect to glucose transport, as they
exhibit acute insulin-stimulated increases in transport of up to 30-fold (fat)
7Figure 1.1
Predicted membrane topology of the facilitative
glucose transporter family
o
::s::/0
9and 10-fold (muscle). In 1980, Cushman and Wardzala, and independently
Suzuki and Kono, first showed that in unstimulated adipose cells, glucose
transporters (now known to be GLUT-4)were predominantly associated with a
light microsome fraction of the cells. Upon insulin stimaulation these
transporters were recruited or translocated to the plasma membrane. Thus, it
seemed probable that these tissues express a novel GLUTisoform. GLUT-4is
expressed at the highest levels in adipose tissue and skeletal muscle, and a
substantial body of evidence now suggests that this isoform is the "insulin-
responsive" glucose transporter. GLUT-4 is unique within the facilitative
glucose transporter family, as under conditions of low circulating levels of
insulin, the majority of GLUT-4is sequestered within a unique intracellular
membrane compartment. Under these conditions only 5% of GLUT-4 is
present at the surface of the cell and available to transport glucose into the
cell. Thus, glucose transport is rate-limiting for cellular glucose metabolism.
When the circulating glucose concentration increases, this acts as a stimulus
for pancreatic s-cells to secrete the peptide hormone, insulin. Upon insulin
binding to the insulin receptor, the receptor undergoes a tyrosine-
autophosphorylation event. An intracellular pathway is subsequently
activated which finally results in the movement of the intracellular pool of
GLUT-4to the cell surface, a process generally referred to as translocation
(see section 1.3). Figure 1.2 is a diagrammatical model representing GLUT-4
translocation. The movement of GLUT-4 to the plasma membrane has the
effect of dramatically increasing the rate of glucose uptake into the cell,
thereby reducing the concentration of circulating glucose. The glucose is
phosphorylated to glucose-6-phosphate before being either utilised to
produce metabolic energy in the form of ATP, or being stored within the cell
as glycogen or triacylglycerides.
10
This GLUT-4-rich intracellular pool is the subject of much debate and is
currently being characterised by a number of laboratories. It is hoped that
by understanding the targeting and translocation of GLUT-4 it may then be
possible to fully comprehend the mechanism by which insulin stimulates the
movement of
11
Figure 1.2
Diagrammatic representataion of GLUT-4
translocation in skeletal muscle and adipose
tissue.
This figure illustrates the slow, constitutive recycling of the insulin-
stimulated glucose transporter, GLUT-4, through the classical endosomal
membrane recycling pathway. Upon insulin stimulation the intracellular
GLUT-4 pool is quickly translocated to the cell surface, resulting in a rapid
increase in glucose uptake.
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this glucose transporter, and therefore increases the uptake of glucose into
the insulin-responsive tissues.
A further benefit in understanding the mechanism of insulin action may be
in pin-pointing the exact locations of the defects in the system characterised
by disease states such as non insulin-dependent diabetes mellitus (NIDDM)
and insulin resistance. Detailed review of the cell biology of GLUT -4 is beyond
the scope of this thesis, and the interested reader is referred to Gould (1997).
1.3 The mechanism and effects of insulin action.
1.3.1 Production of insulin
Insulin is a 5.8kDa polypeptide hormone secreted by the pancreatic ¥'-cells
and is an important regulator of anabolic metabolism. Sanger in 1953 showed
that bovine insulin consists of two chains, an a chain of 21 residues and a fJ
chain of 30 residues, which are covalently linked by two disulphide bonds.
Insulin is synthesised as a single polypeptide chain, preproinsulin, which
contains a nineteen amino acid signal sequence which directs the nascent
chain to the endoplasmic reticulum. In the lumen of the endoplasmic
reticulum the signal peptide is cleaved to form proinsulin which contains
approximately thirty residues absent in the mature peptide. These thirty
residues are called the connecting peptide (Cvpeptide), which is proteolysed
when proinsulin passes through the Golgi apparatus and reaches the
secretory granules. Insulin is secreted from the secretory granules in the
pancreas when the membrane of the granule fuses with the membrane of the
cell.
14
1.3.2 The insulin receptor
The insulin receptor is an integral membrane protein which resides in the
plasma membrane of the cell and is a tetrameric protein composed of two er-
subunits that are each linked to a K-subunit and to each other by di-sulphide
bonds. The receptor is a member of the tyrosine kinase family and behaves
like a classical allosteric enzyme. The o-subunits are located entirely outside
the cell and contain the insulin binding site(s) whereas the intracellular part
of the K-subunit contains the insulin regulated tyrosine protein kinase. From
stoichiometric studies 1-2 insulin molecules bind per receptor with the
binding sites displaying negative co-operativity, and the ligand binding
determinants being mapped to a distinct region within the first 500 amino
acids of the «-subunit. The unoccupied a-subunit of the insulin receptor
inhibits the tyrosine kinase activity of the K-subunit. Several functional
regions have been defined in the K-subunit including the ATP binding
domain and autophosphorylation sites in the intracellular juxtamembrane
region, a regulatory r~f;ion and the COOH terminus. Tyrosine
phosphorylation appears to occur through a trans mechanism in which
insulin binding to the a-subunit of one aR-dimer stimulates the
phosphorylation of the adjacent covalently linked K-subunit [for review, see
White & Khan (1994)]. Phosphorylation of all three tyrosine residues within
the YxxxYYmotif of the regulatory region increases kinase activity 10-20
fold. Mutations of tyrosines 1146, 1150 and 1151 either singularly or
collectively within this domain of the R-subunit result in a progressive
reduction in insulin-stimulated kinase activity and additionally a parallel loss
in biological activity. The structure of the insulin receptor is illustrated in
figure 1.3.
15
Figure 1.3
The structure of the insulin receptor.
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1.3.3 Control of the insulin receptor
As well as being under the influence of tyrosine phosphorylation, the insulin
receptor is also phosphorylated on serine and threonine residues in the basal
state in response to stimulation by insulin, cAMP analogues and phorbol
esters. The combination of ligand binding, tyrosine phophorylation, and
serine/threonine phosphorylation, provide three levels of control which are
sensitive to extracellular messengers and intracellular events. Another
mechanism of control may be tumour necrosis factor-« (TNF-n) which has
been shown to cause insulin resistance in adipose tissue, possibly through
inhibition of autophosphorylation and kinase activity [Hotamisligil et al.
(1993)].
The intracellular juxtamembrane region of the insulin receptor ~-subunit is
essential for signal transmission as replacement of tyrosine 960 with alanine
impairs receptor signal transmission even though autophosphorylation in
the other regions is normal and the kinase activates fully in vitro. This may
be due to the inability of the mutant receptors to phosphorylate exogenous
receptor substrates, such as insulin receptor substrate-I (IRS-I). Some
mutations in the juxtamembrane region may be rescued with overexpression
of IRS-I.
As well as signal transduction, the insulin receptor mediates insulin
internalisation. Internalisation of the receptor, with bound insulin, via
endocytosis leads to the degradation of insulin by its targeting to the
lysosommal system, with the majority of unoccupied receptors being recycled
back to the plasma membrane. The site of insulin receptor signalling in this
recycling is not clear.
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1.3.4 Insulin receptor signalling
After the tyrosine and serine threonine phosphorylation events the
"activated" receptor has the capacity to phosphorylate target proteins. The
most well documented of the target proteins is the Insulin Receptor Substrate-
1(IRS-I). IRS-l has a predicted molecular weight of 131 kilodaltons and is a
specific substrate for the insulin and IGF-l receptors. Initially it was detected
with the use of high affinity anti-phosphotyrosine antibodies and has since
been purified and cloned from several sources. IRS-l contains multiple sites
for tyrosine and serine/threonine phosphorylation in motifs recognised by
various kinases and these multiple phosphorylation sites result in the
protein migrating with an apparent molecular weight of 180 kDa. At least
eight tyrosines in IRS-l are phosphorylated by the activated insulin receptor.
The phosphorylated IRS-l is recognised by the src homology 2 (SH2)domains
of a plethora of signalling proteins via specific phosphorylated tyrosine
residues.
1.3.5 Insulin receptor signalling - PI-3' kinase
Phosphatidyl inositol-3' kinase (PI-3' kinase) was the first SH2 containing
protein that was found to associate with IRS-I. PI'-3 kinase is composed of a
110-kDacatalytic subunit and an 8S-kDa regulatory subunit which contains
the two SH2domains. The SH2domains have been shown to specifically bind
phosphorylated IRS-! in vivo and in vitro. [Sun et al., (1993)] The activation
of PI'-3 kinase occurs when both SH2 domains are occupied with a
phosphotyrosine in a YxxMor YMxMmotif (where x is any amino acid). This
sequence corresponds to an immunoreceptor tyrosine activation motif
(ITAM). Such motifs are common in IRS-I. The biological role of IRS-l will
be discussed in later chapters of this thesis.
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1.3.6 Insulin receptor signalling - Syp
SH-PTP2(syp) is a protein tyrosine phosphatase which also contains two SH2
domains and binds to tyrosine 1172 of IRS-I. This association of SH-PTP2with
phosphoproteins such as IRS-l activates the phosphatase, and suggests a role
for IRS-l in the activation of this signalling pathway [Kahn(1994)].
1.3.7 Insulin receptor signalling - MAP kinase
Another protein that binds to IRS-l is the small cytoplasmic protein, GRB-2
which contains two Src homolgy 3 (SH3) domains, which recognise proline-
rich amino acid sequences, and one SH2domain. GRB-2binds to tyrosine 895
in IRS-I,and is thought to act as an "adaptor molecule" linking the guanidine
nucleotide exchange factor for P21ras termed mSOS to tyrosyl
phosphoproteins, such as IRS-l. The binding of GRB-2/mSOSto IRS-l may
mediate the insulin stimulation of p21ras. Rashas been shown to bind to Raf-
1 serine/threonine kinase, which in turn activates MAP kinase via
phosphorylation and activation of MAPkinase kinase. Thus the binding of
GRB-2to IRS-l might provide a pathway for insulin regulation of Ras.
The MAPkinase pathway results in the activation of several other kinases,
such as p90 S6 kinase. S6 kinase activates a phosphatase which
dephosphorylates and therefore activates glycogen synthatase, the rate
limiting enzyme in glycogen synthesis.
1.3.8 Insulin receptor signalling - synopsis
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Insulin action is mediated by a cascade of covalent and non-covalent
interactions that centre around IRS-!. Insulin binding to the receptor on the
cell surface leads to the phosphorylation of IRS-! which serves as the
docking protein for several intracellular enzymes and docking proteins. It is
the docking of these proteins that leads to the multiple signals generated by
the action of insulin [Khan (1994)]. The events listed above involving IRS-!
indicate the importance of IRS-! in most, if not all, of insulin's biological
actions. The insulin receptor signalling pathway is summarised in figure 1.5.
1.3.9 Insulin receptor signalling - mitogenesis
The role of insulin as a mitogen has been studied in Chinese Hamster Ovary
(CHO)cells. In cells overexpressing IRS-! there was a two-fold increase in
thymidine incorporation upon insulin stimulation. However, when IRS-!
levels were reduced using antisense eDNA, there was a reduction in the
response and sensitivity of the mitogenesis following insulin stimulation.
Such studies indicate a key role for IRS-! in mitogenesis.
IRS-! is absent from the 320 myeloid progenitor cell line, which is also
unable to produce a mitogenic response to an insulin stimulus. Ectopic
expression of IRS-! in the 320 line results in insulin stimulated IRS-!
phosphorylation and DNAsynthesis, thus proving that IRS-! is required for
the mitogenic response produced by insulin.
Although IRS-! plays a key role in bringing about the biological actions of
insulin, the signalling pathways downstream of IRS-! remain unclear. The
main role of insulin is to play a key role in glucose homeostasis. This is
achieved by the translocation of the facilitative glucose transporter, GLUT-4,
21
and the subsequent increase in uptake of circulating glucose, thereby
reducing the concentration of blood glucose.
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Figure 1.4
Diagrammatic representation of insulin receptor
re-cycling.
* - indicates that it has not been determined if the receptor is still signalling
at these intracellular locations.
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Figure 1.5
The insulin receptor signalling pathway through IRS-l
and associated proteins.
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As mentioned above insulin also produces a variety of other biological
responses. It has been noted that insulin is a mitogen, inducing growth in a
variety of tissues. Furthermore insulin has been shown to stimulate the
sympathetic nervous system. Finally insulin plays a key role in insulin
metabolism. It is widely acknowledged that insulin resistance mainly occurs
with respect to glucose transport in peripheral tissues, with the remaining
properties of insulin unaffected (see below).
1.3.10 Cation transport
Insulin stimulates the Na' IKI ATPase,Ca2+ ATPaseand the Nat IHI antiport as
well as potential and receptor mediated Ca2t channels., The net effect of
insulin is to reduce the concentration of intracellular Nat, Ca2t, and H+,and
also to elevate Mg2+. Vascular smooth muscle cells will show diminished
responses under these circumstances. The role of cation transport in insulin
resistance will be discussed in later chapters of this thesis. Experimental
evidence suggests that insulin resistance extends to b~)~hthe Na+/K+ ATPase
and the Ca2+ATPase. This leads to a reduction in the activity of these enzymes
in insulin resistant states such as hypertension and obesity. Decreased
activity of the Na"IK+ ATPase and Ca2+ ATPase could lead to increased
intracellular Ca2+ concentration, which is a determinant of vascular smooth
muscle contractility. If on the other hand the Na+IH+ antiporter retains
normal sensitivity to insulin, the resultant hyperinsulinaemia will augment
Nat IH+ exchange. This antiporter is a known genetic marker for primary
hypertension, and is a ubiquitous transport system invovled in the regulation
of cell volume, growth, intracellular pH and also Cal+ exchange.
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1.4 Insulin resistance
Insulin resistance is a disease characterised by the reduced ability of insulin
to exert its effects in peripheral tissues, skeletal muscle and adipose tissue.
The disease is characterised by the patient displaying hyperglycaemia in the
face of normal or even elevated circulating concentrations of insulin. One
effect of insulin resisance is the marked decrease in insulin-stimulated
glucose uptake into skeletal muscle and adipose tissue. If severe. insulin
resistance can lead to overt Non-Insulin Dependent Diabetes Mellitus (NIDDM)
and has been associated with a number of other disease states including
obesity, Impaired Glucose Tolerance (IGT),NIDDM,hypertension, pregnancy
and steroid therapy. The fact that NIDDM,obesity and essential hypertension
often occur together in a clinical situation implies that there may be common
factors in the underlying pathology of these conditions [Reaven et al.,
(1989)].
The mechanism of insulin resistance is poorly understood and one of the aims
of my project was to try and elucidate the role of the facilitative glucose
transporters, and in particular GLUT-4, in insulin resistance associated with
hypertension.
1.5 Insulin resistance and the glucose transporter
GLUT-4.
As previously stated GLUT-4is the "insulin-responsive glucose transporter"
which translocates to the cell surface under the stimulus of insulin. The
rapid recruitment of GLUT-4 to the muscle and fat cell surface greatly
increases the capacity of the cell to import glucose, convert it into glucose-6-
phosphate and finally glycogen, to decrease circulating levels of blood
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glucose. In section 1.4 insulin resistance was characterised as the failure of
insulin to result in efficient glucose disposal, and in particular a failure of
insulin to produce its normal increase in glucose transport in target tissues.
Although skeltal muscle is the main site of glucose disposal, the majority of
work on insulin resistance has been performed on adipose tissue. Adipose
tissue only accounts for 5-20%of whole body glucose disposal but is a suitable
tissue to study as it contains GLUT-4and is readily isolated or grown in
culture. Muscle tissue is difficult to work with and in particular skeletal
muscle is very difficult to isolate and separate into subcellular membrane
fractions.
The most common disease linked with insulin resistance is diabetes mellitus.
This disease is responsible for a great deal of morbidity and mortality in the
western world. However, the majority of patients suffering from this ailment
are not dependant upon insulin treatment, Le. they suffer from NIDDM.
NIDDMis characterised by hyperglycaemia in the face of normal or elevated
levels of circulating insulin. It has been established that the abnormality
impairing insulin's ability to stimulate glucose disposal into peripheral
tissues in such individuals generally lies distal to the binding of insulin to its
plasma membrane receptor [Reaven et al., (1989). The full signalling
pathway from binding of the receptor to the uptake of glucose has not been
fully elucidated, see Kahn (1994), so the abnormality could lie anywhere from
the generation of the signal to the glucose uptake itself. Research efforts are
currently focused on the three main areas best understood in the process:
firstly activation of the insulin receptor-associated tyrosine kinase, secondly
glucose uptake in the cell and finally GLUT-4trafficking and targeting.
Within whole body glucose homeostasis, GLUT-4 is the most important
facilitative glucose transporter [Gould& Holman (1994)]. As stated previously
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(section 1.2), expression of this isoform is restricted to tissues which exhibit
acute, insulin-stimulated glucose transport (skeletal muscle, brown and white
adipose tissue and cardiac muscle) and is unique by virtue of it's almost
exclusive intracellular location in the absence of insulin. During
postprandial hyperglycaemia, circulating insulin signals this transporter to
translocate from intracellular locations to the plasma membrane, where its
presence is associated with a rapid and massive increase in glucose uptake.
Following the cloning of the insulin-regulatable glucose transporter by
James and co-workers in 1989 there has been an exponential growth in
research within this topic. The cloning and purification of the transporter
led to the production of anti-GLUT-4 antisera enabling the protein to be
quantified in tissues. Furthermore a considerable amount of research has
been directed towards the understanding of GLUT-4translocation. The signal
which recruits GLUT-4to the cell surface remains unclear but it is now
becoming more apparent that GLUT-4functioning is defective both in animal
models and human insulin resistance.
1.5.1 The nature of GLUT-4 defects in insulin resistance
Patients with NIDDMhave been examined extensively for mutations of the
GLUT-4 gene which might result in a dysfunctional transporter. Point
mutations have been noted but these occur in too small a percentage of cases
for them to be considered an important aetiological factor in insulin
resistance [reviewed in Gould, (1997)]. Furthermore, gene defects would be
expected to underlie an irreversible form of insulin resistance, however the
phenomenon of insulin resistance appears to be subject to a number of
influences, and is not always irreversible ego gestational diabetes mellitus
(GDM).
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It is unsurprising then that functional impairment of insulin-stimulated
transport in NIDDM patients has emerged as being more important than
genetic defects and the basis for this impairment is becoming apparent.
The types of defect found in insulin-regulatable glucose transport can be
divided into two groups,
i) where there is cellular depletion of GLUT-4
and/or
ii)where the protein is apparently expressed at normal levels
but fails to translocate effectively to the cell surface in response
to insulin, owing to a defective signal pathway following
binding of insulin to its receptor.
1.5.2 Cellular depletion of GLUT-4 levels and insulin resistance
in adipose tissue
In adipose tissue from obese and NIDDM patients there is a clear and well
documented reduction of GLUT-4expression compared to that of lean controls.
Furthermore, insulin-stimulation of GLUT-4 translocation has been shown to
be impaired in adipocytes from NIDDM patients [reviewed in Gould, (1997)].
These patients have lower than normal levels of GLUT-4mRNA, indicative of a
pre-translational effect. A similar picture is observed in GDM [Garvey et al.
(1993)]. GLUT-4 levels were shown to be severly depleted in half the GDM
patients studied but in addition all the GDM cohort in this study exhibited
abnormal targetting of the protein to an intracellular compartment from
which it could not be effectively translocated to the cell surface upon insulin
stimulation [Garvey et al., (1988).
31
As yet the influences upon GLUT-4expression are poorly understood as are
the factors underlying transporter depletion in diabetes. However, the
signalling nucleotide cyclic S'-monophosphate (cAMP) has been found to
have a repressive effect on the GLUT-4gene. It is possible that elevated levels
of cAMPknown to be present in diabetic adipocytes may contribute to poor
expression of the transporter [Shepherd & Kahn (1993)]. Secondly,
hyperinsulinaemia present in the early stages of NIDDMmay play a causative
role in in the down-regulation of insulin-stimulated glucose transport. The
recent identification of the GLUT-4promoter and the ability to use transgenic
technology to engineer tissue-specific expression of reporter genes should
provide key insights into the regulation of this gene, and thus alow the
identification of the factors which control GLUT-4expression [reveiwed in
Gould, (1997)]
1.5.3 Insulin resistance in skeletal muscle
In skeletal muscle the nature of insulin resistance has proven to be different,
implying that there are tissue-specific diffferences in the pathology of
insulin resistance as well as in GLUT-4 expression under normal
circumstances [Pedersen et al., (1990)]. Most studies have shown no change
in muscle cellular GLUT-4expression at both the level of mRNAand protein
concentrations in insulin resistant patients [Pedersen et al., (1990)] •• Onlythe
plasma membrane-associated GLUT-4 level was lower, suggesting an
abnormality in the translocation of GLUT-4in response to insulin. The
majority of studies present in literature suggest that altered GLUT-4
expression does not contribute to skeletal muscle insulin resistance
[Shepherd & Kahn, (1993)]. Despite some reports of decreased GLUT-4
expression in skeletal muscle of individuals with NIDDM,it is now generally
accepted that skeletal muscle GLUT-4levels are unchanged in individuals
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with NIDDMcompared to age-and weight-matched control subjects [Pedersen
et. al. (1991)]. This was recently borne out by the study of Bjorback et al.
(1994) which analysed the GLUT-4promoter of insulin resistant subjects.
Although some genetic variants were discovered. none were considered likely
to impair expression of the gene and therefore cannot be implicated in
insulin resistance.
The overwhelming number of reports present in the literature suggest that
reduced expression of GLUT-4does not contribute to skeletal muscle insulin
resistance [Shepherd & Kahn. (1993)]. It further suggests that the defect in
this tissue may lie either on the pathway of insulin-signalling or transporter
translocation. Figure 1.6 illustates the potential sites of insulin resistrance in
relation to insulin-stimulated GLUT-4translocation. Thus, understanding
GLUT-4trafficking and targeting remain key goals for future reasearch. This
point will be further discussed in chapters 3 and 4 of this thesis.
1.6 Insulin resistance and the relationship with
hypertension.
Insulin resistance is characterised by hyperglycaemia and
hyperinsulinaemia. This disease state is known to occur in tandem with other
conditions such as obesity and non-insulin dependant diabetes mellitus
(NIDDM). One other disease state that commonly occurs with insulin
resistance is hypertension. The relationship between these two disease states
is not straightforward. Rocchini et al. (1995) state that approximately SO%of
hypertensive subjects have insulin values within 1 standard deviation of the
normotensive population and were therefore not insulin resistant.
Nevertheless, he argued that the two situations are closely linked, as
evidenced by SO%of this group exhibiting some hypertension. The link
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between hypertension and insulin resistance is complex and multifactional,
and has been extensively reviewed recently so it will not be re-iterated here.
However, it should be noted that insulin resistance and hypertension often
occur in the same patient, and are in many cases inextricably linked.
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Figure 1.6
The potential sites of insulin resistance in adipose
tissue.
Under basal conditions, approximately 95% of GLUT-4 is located
intracellularly in a pool of vesicles, the nature of which is poorly understood.
GLUT-4undergoes a slow rate of constitutive recycling between the plasma
membrane and this intracellular site, a process which is thought to occur
through coated pits and entry into the endosomal system. Upon insulin-
stimulation, 40-50% of the intracellular pool translocates rapidly (within
minutes), giving rise to 20-30 fold increases in the cell surface GLUT-4levels,
and so accounting for the large increase in glucose transport observed under
such conditions. as Circulating glucose and insulin levels fall. there is a
reversal of this situation, with the GLUT-4 becoming sequestered in the
intracellular pool. This model is based on studies on adipocytes. Potential
sites of insulin resistance shown are as follows: (1) Reduced binding of
insulin to its plasma membrane receptor or impaired activation of the
receptor-associated tyrosine kinase. (2) Impaired intracellular insulin
signalling pathway. Both defects would render cells insulin-resistant for
glucose transport independently of any defects in transporter expression or
function. (3) Defective translocation of GLUT-4to the cell surface. In this
case, normal levels of GLUT-4are present in the intracellular pool, but a
defect in the mechanism responsible for moving this pool to the cell surface
results in blunted insulin-stimulated transport. (4) Reduction in the
intracellular pool of GLUT-4. In this scenario, translocation of GLUT-4occurs
as normal, but there is a reduced level of insulin-stimulated glucose transport
due to a profound reduction in the GLUT-4available for translocation. (5)
Mistargeting of GLUT-4to a non-translocable pool. This mislocalisation of
GLUT-4to a site from which it cannot be targeted would have the effect of
reducing insulin-stimulated glucose transport.
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Hypertension can precede insulin resistance, but the converse is also true,
with insulin resistance preceding hypertension. However, note that not all
insulin resistant patients become hypertensive nor do all hypertensive
patients become insulin resistant, hence the relationship between these
clinical conditions is complex [Reaven et al., (1989, 1991)].
1.6.1 Insulin resistance may be pathway specific
Although insulin resistance is characterised the impaired ability of insulin to
cause whole body glucose disposal, some or all other physiological actions of
insulin may be preserved. Potentially the most important of these with
respect to hypertension is the ability of insulin to induce renal sodium
retention. It has been demonstrated that obese adolescents have "selective"
insulin resistance as they are resistant with respect to glucose uptake by
skeletal muscle yet are still sensitive to the renal sodium-retaining effects of
insulin. Also, Ferrannini et al. (1987) have demonstrated in non-obese
essential hypertensives that insulin resistance is selective, tissue specific and
pathway specific. The selectivity predominantly involves glucose
metabolism, but also amino acid and fatty acid metabolism to a smaller degree.
The main site of insulin resistance is skeletal muscle, with the liver and
adipose tissue affected to a lesser extent. In terms of pathway specificity it
appears that only the glycogen synthesis pathway is usually affected
although in cases of diabetic ketoacidosis all anabolic pathways are resistant
to the effects of insulin. Therefore in any individual the degree to which the
insulin resistance is tissue and pathway specific may determine whether
hypertension will develop.
Insulin resistance may result in hypertension through changes in vascular
structure and function, activation of the sympathetic nervous system and
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enhanced renal sodium retention. Aspects of these points will be further
discussed in subsequent chapters as necessary.
1.7 Animal models of hypertension and insulin
resistance.
The use of rodent models to study insulin resistance and hypertension has
produced conflicting results regarding the aetiology and underlying
pathology responsible. This may in part be due to the model systems
displaying varying degrees of insulin resistance, perhaps reflective of the
heterogeneity of the disease, but it may also be accounted for by difficulty in
the preparation of sub-cellular fraction of tissues such as skeletal muscle.
Furthermore the employment of different techniques to study the tissues
under investigation may produce inconsistent results.
1.7.1 GLUT-4 in animal models of insulin resistance
GLUT-4levels in animal models of insulin resistance have been extensively
studied and reviewed [Livingstone et al., (1994)]. This thesis concerns GLUT
levels in animal models of insulin resistance associated with hypertension.
Some of these models are discussed below in brief.
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1.7.2 GLUT-4 in rodent models of genetic hypertension
Obese Zucker Rat.
The obese Zucker (fa/fa) rat model was initially employed as a model of
insulin resistance associated with obesity. This model has been extensively
studied with respect to insulin signalling and glucose uptake into the insulin-
sensitive tissues. The results proved that this model was indeed insulin
resistant as the animal displayed normoglycaemia with elevated circulating
levels of insulin and diminished insulin-stimulated glucose uptake, in
adipocytes and all major muscle groups. Further studies revealed that this
animal was hypertensive when compared with control strains and therefore
also represents a useful model for this condition.
Skeletal muscle from these animals exhibit no change in GLUT-4expression
compared with lean control animals, and impaired insulin-stimulated GLUT-4
translocation to the plasma membrane is again a likely possibility to account
for the insulin resistance observed.
Male rats of a related strain, the ZDF/drt/fa Zucker rat, are also obese and
insulin-resistant, but go on to develop overt diabetes. Interestingly, in this
strain, GLUT4levels have been found to be significantly reduced in both
skeletal muscle and adipose tissue, accounting for the insulin resistance. The
level of GLUT-4 expression in the obese animal has been restored by
combating the hyperglycaemia, suugesting that this may be contributing to
the impaired expression of the transporter. Reduced GLUT4in this animal
model appears to be decisive in causing the diabetes, since in other respects
the animals are similar to their respective non-diabetic strains.
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Spontaneously Hypertensive Rat (SHR).
The SHRis the most studied rodent model of genetic hypertension. As well as
hypertension, the SHR exhibits insulin resistance and hyperinsulinaemia
compared with control strains. Insulin stimulation of glucose uptake into
adipocytes isolated from these animals is impaired, and there is also reduced
uptake of glucose into skeletal muscle. The site of the insulin resistance
appears to be distal to the insulin receptor in the signalling process and
Reaven er al. suggest that this defect lies at the level of glucose transporter
function. Howeverit is important to note that doubt has been expressed about
the existence of insulin resistance in this strain. Some have interpreted the
appearance of normoglycaemia and hyperinsulinaemia to imply insulin
resistance in SHRs, and have provided evidence for reduced maximal
response to insulin. However, this is controversial as another study has
demonstrated increased sensitivity and unchanged maximal responses to
insulin, using hyperinsulinaemic euglycaemic clamp techniques. This
conflict in the published literature awaits resolution.
It is of interest that skeletal muscle from SHRsexhibit similar levels of GLUT-4
to two control strains. A further point of note is that the study clearly
demonstrates the GLUT-4content of the intracellular pool is unchanged in
the hypertensive strain. This resembles the situation in skeletal muscle from
human studies on insulin resistance, and suggests that translocation of the
transporter may be defective.
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SHR/N-Cp.
A relative of the SHR, the obese diabetic SHR/N-cp, exhibits
hyperinsulinaemia and is also hyperglycaemic. It inherits obesity as an
autosomal recessive trait and develops NIDDMalong with characteristic
diabetic complications. In the obese SHR/N-cp, GLUT-4 levels in the skeletal
muscle are significantly reduced when compared to the lean SHRs. This
change is likely to be significantly involved in the dramatic insulin
resistance associated with these obese animals. At present little information
is available regarding the relative levels of hypertension between the two
strains, but it is interesting to note that the obese SHR/N-cp model exhibits
marked hyperinsulinaemia and is diabetic, as evident by 20-fold higher
serum glucose levels and 2-fold higher insulin levels than the lean SHR/N-cp
control animals. This observation is strikingly similar to results noted with
the obese diabetic ZDF/drf-fa rat, which exhibited decreased levels of GLUT-4
in muscle coincident with hyperglycaemia.
Dahl rat
The Dahl rat is another model of genetic hypertension which has been found
to be insulin-resistant and hyperinsulinaemic compared with its control
strain; the Sprague-Drawley rat. Two strains of the Dabl rat have been
studied, the Dahl-S rat which becomes hypertensive when fed on a high salt
diet, and the Dahl-Rrat which does not develop hypertension but still exhibits
insulin resistance. Isolated adipocytes from both these strains show impaired
glucose uptake in response to insulin; therefore the insulin resistance is not
dependent on the animal being hypertensive, nor is it a direct function of its
salt intake. Asyet, glucose transporter isoforms have not been quantified in
insulin-sensitive tissues from this animal model. It will also be of interest to
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assess changes in skeletal muscle GLUT-4in the context of the glycaemic and
insulinaemic status of these animals.
Milan rat
The Milan hypertensive strain is an inbred strain of rat which spontaneously
develops hypertension, unlike its genetic control, the Milan normotensive
strain, which exhibits normal blood pressure. As with the other animal
models discussed above, development of hypertension in these animals is
associated with hyperinsulinaemia and insulin resistance, but these two
strains exhibit identical fasting glucose levels. In the course of this project I
have shown that the male Milan hypertensive strain has reduced levels of
GLUT-4 in skeletal muscle compared with the normotensive strain, and that
this decreased expression is primarily associated with a decrease in the levels
of GLUT-4 in the insulin-sensitive intracellular pool. Interestingly no
change was observed in the level of expression of GLUT-4in the adipocyte
membranes from these animals.
Stroke-prone Spontaneously hypertensive rat (SHRSP)
In chapter 4 of this thesis we undertook a novel study examining the levels of
the facilitative glucose transporters in the SHRSPrat strain, looking at the
SHRSPF2 progeny. The SHRSPoriginally come from Okamoto's group in
Japan around 1973. The F2 generation is a classical reciprocal cross with
cross 1 = WKYmale x SHRSPfemale and cross 2= WKYfemale x SHRSPmale.
The reason for this cross was to investigate the importance of the Y
chromosome inheritance and to segregate the WKYand SHRSP genome.
Throughout the study the rats have unlimited access to rat chow and water.
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They are kept in a regime of 12hr light 12hr darkness. light 7am to 7pm.
night 7pm to 7am.
The blood pressures are variable in the parentals with the max systolic being
220-230for SHRSPand 140-150for WKY.(Pressuresare in mm mercury). The
pressures were all measured by radiotelemetry ie a probe was inserted into
the abbominal aorta. The probe was linked to a battery
which was sutured to the abdominal wall. Telemetry was used to reduce the
stress on the animals during blood pressure (bp) measurements. The F2
progeny display blood pressures which range from normotensive to
extremely hypertensive. Using this data we wished to examine the
correlation between blood pressure and facilitative glucose transporter
levels.
1.7.3 The use of hypertensive, insulin resistant
rodent model systems
Insulin resistance is a heterogeneous condition with different characteristics
in different pathophysiological states. Thus, the insulin resistance associated
with essential hypertension is subtly different from that observed in obesity
or type II diabetes, as the former is confined mainly to peripheral tissues
(muscle and adipose tissue) and not the liver, and also seems to be limited to
non-oxidative pathways of intracellular glucose utilisation [Livingstone &
Gould (1995)].
The development of insulin resistance in both type I and type II diabetes has
been extensively studied in both human and rodent models of the disease. It is
now well established that defects in the glucose transport systems present in
either peripheral tissues or the pancreatic b-cells are potentially important
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in both the onset and development of the disease [James & Piper (1994); Kahn
(1992)].
Glucose transport across the plasma membrane of animal cells is mediated by
a family of glucose transporter proteins of the facilitative diffusion type.
Each transporter is the product of a distinct gene and is expressed in a highly
tissue specific fashion [see section 1]. Within the context of diabetes, the most
important transporter would appear to be GLUT-4. It is clear from a variety of
studies that defects in GLUT-4 expression, translocation or targeting (or a
combination of all three) may underlie the inability of insulin to stimulate
effectively glucose transport in adipocytes and muscle in a range of diseases
[Livingstone et al., (1995). Thus, understanding the regulation of GLUT-4
expression and function represent questions of considerable importance, not
only in the field of diabetes, but also within the context of hypertension, and
other pathophysiological states associated with insulin resistance. This is one
of the central themes of this thesis.
However, the contribution of other GLUTisoforms to dysregulated glucose
homeostasis should not be overlooked. GLUT-2(liver and pancreatic s-ceus)
and GLUTs1 and 3 (in brain/nerve) may also be defective in certain clinical
conditions, and their expression has been poorly studied in hypertensive
model systems to date.
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1.8 Aims of the study.
The main aim of the study is to examine the sub-cellular distribution of the
insulin-stimulated facilitative glucose transporter, GLUT-4,in the mildly
hypertensive, insulin resistant Milan rat strain. The focus will therefore be
placed upon the insulin-sensitive tissues, fat and muscle. The reasoning
behind this is to determine if there are any defects either in expression or
localisation, or both, that may offer an explanation of insulin resistance in
this strain.
Furthermore, GLUTs1, 2 and 3 will be studied to build up a profile of the
facilitative glucose transporter distribution within the brain (GLUTs1 and 3)
and hepatic tissue (GLUT-2)of the Milan rat.
As a follow up to the initial aims I also examined the GLUT-4 content of the
tissues named above in the progeny of an F2 generation of SHRSPstrain. The
purpose of this was to determine if this insulin resistant, hypertensive strain
also possessed a defect in the amount of GLUT-4located in the intracellular
membrane pool. The SHRSPF2 progeny are animals with a wide range of
blood pressures, therefore I also wanted to examine whether there was a
correlation between the degree of hypertension from normotensive to
extremely hypertensive, and the level of GLUT-4present within each of the
membrane fractions.
GLUTs1, 2 and 3 were also investigated in the SHRSPF2 progeny, GLUT-2in
liver and GLUTs1 and 3 neuronal tissue. This gives detailed information on
the amount of facilitative glucose transporters present in the SHRSP rat
strain.
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Additionally I examined the amount of PI-3' kinase present in the soluble
fraction of SHRSPmuscle. As stated previously PI-3' kinase is a key molecule
in the signalling pathway of the insulin receptor and any defect, or
reduction in expression, may play an important role in insulin resistance.
My final study looked at models of insulin resistance and the role of sex
steroids. It has been acknowledged for some time that women on hormone
replacement therapy or those on the contraceptive pill are more susceptible
to insulin resistance. Therefore, I examined what effect treating 3T3-Ll
adipocytes with oestrogen and its derivatives would have upon insulin-
stimulated glucose transport. If any defects were noticeable I would then
examine the GLUT-4content of cells treated with oestrogen or any of the
derivatives.. This system was chosen in the hope of developing an in vitro
model of insulin resistance.
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Chapter 2
Materials and Methods
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2.1 Materials
All reagents used in the course of the project were of a high quality and were
obtained from the following suppliers:
2.1.1 General Reagents
Bio-Rad Laboratories Ltd, Hemel Hempstead, Hertfordshire, UK
cellophane membrane backing
N, N, N', N'-tetramethylethylenediamine (TEMED)
pre-stained SOS-PAGEStandards (myosin, s-gatactosidase, BSAand ovalbumin)
Diversified Biotech, Boston, MA, U.S.A
Quantigold
Fisons, Loughborough, Leicestershire, UK
acrylamide
ammonium persulphate
Folin and CiocaIteau's phenol reagent
glucose
glycerol
glycine
Hepes
hydrochloric acid
methanol
N, N' methylene-bis-acrylamide
potassium chloride
sodium dodecyl sulphate (SOS)
sodium chloride
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sodium dihydrogen orthophosphate dihydrate
sodium diarninoethanetetra-acetic acid (EDTA)
sodium hydrogen carbonate
trichloroacetic acid
Gibco BRL, Paisley, Lanarkshire, UK
Tris base
Kodak Ltd, Hemel Hempstead, Hertfordshire, UK
RPX-Omar liquid fixer/replenisher
RPX-Omat liquid developer/replenisher
X-OmatAR film
X-OmatS film
Merck Ltd (BDH), Lutterworth, Leicestershire, UK
calcium chloride hexahydrate
calcium nitrate tetrahydrate
dimethyl sulphoxide
magnesium chloride hexahydrate
magnesium sulphate heptahydrate
Packard Instrument B.V. -Chemical Operations, Groningen, The
Netherlands
Ultima-Flo scintillation fluid
Premier Brands UK, Knighton Adbaston, Staffordshire, UK
Marvel powdered milk
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Schleicher & Schuell, Dassel, Germany
nitrocellulose membrane (0.45,..M)
Sigma Chemical Company Ltd, Poole, Dorset, UK
aprotinin
BSA (A-7030)
bromophenol blue
cytochalasin B
2-deoxy-D-glucose
diisopropyl fluorophosphate (DFP)
DL-dithiothreitol
E64
[JJ-estradiol
estriol
estrone
insulin (porcine monocomponent)
Pepstatin A
sodium deoxycholate
trichloroacetic acid
Triton X-lOO
Whatman International Ltd, Maidstone, UK
Whatman 3mm filter paper
2.1.2 Antibodies
Amersham International Plc, Aylesbury, Buckinghamshire, UK
horseradish peroxidase (HRP)-conjugated donkey anti-rabbit IgG antibody
so
East Acres Biologicals, Southbridge, Massachusetts, USA
rabbit anti-human GLUT-l antibody
2.1.3 Cells
American Type Culture Collection, Rockville, USA
3T3-Ll fibroblasts
2.1.4 Cell culture media and reagents
Gibco BRL, Paisley, Lanarkshire, UK
Dulbecco's modified Eagle'smedium (without sodium pyruvate, with 4S00mg/L
glucose) (DMEM)
10000U/ml penicillin, lOOOOU/mlstreptomycin
trypsin
Flow Laboratories, Irvine, Ayrshire, UK
new born calf serum (NCS)
foetal calf serum (FCS)
2.1.5 Cell Culture Plastics
AS Nunc, DK Roskilde, Denmark
SOml centrifuge tubes
6 crn2 cell culture plates
10 crn2 cell culture plates
8Ocrn2cell culture flasks
6-well cell culture plates
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Bibby Sterilin Ltd, Stone, Staffordshire, UK
sterile pipettes
13.5 ml centrifuge tubes
2.1.6 Radioactive materials
NEN Dupont (UK) Ltd, Stevenage, Hertfordshire, UK
2-deoxy-D-[2,6-3H] glucose
12sI-conjugated goat anti-rabbit IgG antibody
2.2 Buffers and media
2.2.1 Cell culture media
Serum-free DMEM
100U/ml penicillin, 100U/ml streptomycin in DMEM
10% NCS/OMEM
100U/ml penicillin, 100U/ml streptomycin, 10%(v/v) NCS in DMEM
10% FCS/DMEM
100U/ml penicillin, 100U/ml streptomycin, 10%(v/v) FCS in DMEM
Sterile trypsin solution for cell passage
25%(w/v) trypsin in PBS (see General Buffers) was syringe filtered through a
sterile 2"M membrane and stored in 10ml aliquots in SO ml sterile centrifuge
tubes at -20°C.
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2.2.2 General buffers
Phosphate buffered saline (PBS)
lS0mM sodium chloride, 10mM sodium dihydrogen orthophosphate dihydrate,
(pH 7.4).
KRP buffer
64mM NaCI, 2.SmM KCI, 2.SmM NaH2ID4.2H20, 0.6mM MgS04.& H20, 0.6mM
CaClZ,(pH 7.4).
Protein concentration assay: Reagent A
0.025% (w/v) copper sulphate pentahydratel O.OS%(w/v) sodium potassium
tartrate/ 0.25% (w/v) 2.5% (w/v) SOSI 0.2M sodium hydroxide.
Protein concentration assay: Reagent B
A 1:5 dilution of Folin and Ciocalteau's phenol reagent inwater.
2.2.3 SDS-PAGE Buffers
Electrode buffer
25mM Tris-base, 192mM glycine, 0.1% (w/v) SDS.
Sample buffer
93mM Tris hydrochloride pH6.8, 20mM dithiothreitol, 1mM sodium EOTA, 10%
(w/v) glycerol, 2% (w/v) SOS, 0.002% (w/v) bromophenol blue.
The dithiothreitol was added immediately before use.
S3
2.2.4 Protease inhibitor stocks
Pepstatin A
Img/rnl in OMSO.
E 64
10mM in 2mM sodium EOTA.
OFP
200mM in isopropanol.
All protease inhibitor stocks were kept at -20°C.
2.2.5 Western blot buffers
Blot buffer
25mM sodium dihydrogen orthophosphate dihydrate, (pH 6.5).
First wash buffer
lS0mM sodium chloride, SmM sodium dihydrogen orthophosphate dihydrate,
1mM sodium EDTA,O.l%(v/v) Triton X-lOO,(pH 7.4).
Second wash buffer
790mM sodium chloride, SmM sodium dihydrogen orthophosphate dihydrate,
1mM sodium EDTA,0.1% (v/v) Triton X-lOO, (pH 7.4).
Towbln buffer
2SmM tris-base, 192mM glycine, 20% (v/v) methanol, (pH 8.3).
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2.2.6 Muscle buffer
IOmMNaHC03,0.25Msucrose, 5mMNaN3.
2.2.7 S'-nucleotidase assay buffer A
150mMKCI,20mMHepes, 2mMMgCI2.
2.2.8 SH Buffer
0.25M sucrose, 5mMHepes, (pH 7.4).
2.2.9 KRH buffer
O.IM NaCl, 5mMKCI, ImM KH2ID4,O.lmM MgS04.7H20, 2SmMHepes, SOmM
glucose, ImM CaCI2.(pH7.4).
2.3 3T3-Ll Fibroblast culture
2.3.1 Growth of 3T3-Ll Fibroblasts
3T3-Ll fibroblasts were grown on cell culture flasks and plates containing
10%(v/v) NCS/DMEM(section 2.2.1). The medium was replaced every 2 days,
with the cells being kept in an incubator at 3rC in a humidified atmosphere
containing 10%C02.
2.3.2 Trypsinisation of 3T3-Ll Fibroblasts
When the cells were 70-80% confluent they were removed from the flasks
using trypsin. The medium was aspirated from each flask and 5ml of 0.25%
(w/v) trypsin in PBSwas added. The flask was placed in the incubator for 5
minutes, allowing the cells to float, before trypsinisation was stopped by the
addition of the cells to a volume of 10%NCS/DMEM. The diluted cells were
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subsequently seeded onto new cell culture dishes. On average the cells from
one 1Ocm2plate were seeded onto ten 1Ocm2plates.
2.3.3 Preparation of 3T3-L1 Fibroblast Differentiation Medium
Differentiation medium containing 10% FCS (v/v), O.SmM methyl
isobutyixanthine, 0.2SmM dexamethasone, and insulin (1~g/ml) was prepared
as outlined below.
A SOOXstock solution of dexamethasone was prepared by a 1:20 dilution of
2.SmM dexamethasone in ethanol with 10% FCS/DMEM prior to use. A SOOX
sterile stock solution of methyl isobutylxanthine (lBMX) was prepared by
dissolving 55.6 mg IBMX in 1.0 ml of O.3SM KOH and passing the solution
through a 0.22 micron filter. Insulin (lmg/ml)was prepared in 10mM HCI,
and again filtered by passing through a 0.22 micron filter.
3T3-Ll fibroblast differentiation medium was prepared by diluting both the
dexamethasone and IBMX solutions to a 1X concentration in 10% (v/v)
FCS/DMEMand fmally adding insulin to a concentration of Iug/rnl,
2.3.4 Differentiation Protocol for 3T3-L1 Fibroblasts
Cells seeded in 6-well plates were grown and maintained in 10% (v/v)
NCS/DMEM until 48 hours post confluence. At this time the medium was
aspirated and replaced with 2ml per well of differentiation medium which is
described above in 2.3.3. After a further 2 days this medium was aspirated and
replaced with 10% (v/v) FCS/OMEM containing 1~g/ml insulin. The cells
were incubated in this medium for a further 2 days, then the media was
aspirated and replaced with 10%(v/v) FCS/OMEM. Cells were fed every 2 days
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thereafter in this medium. Cells were used between 8-13 days post
differentiation, at which time insulin-stimulated 2-deoxy-D-glucose transport
was maximal.
2.3.S Storage of 3T3-L1 Fibroblasts in liquid nitrogen
Confluent cells were removed from a 7Scm2 flask as in Section 2.3.2 and
resuspended in Sml of 10%(v/v) NCS/DMEM.The suspension was centrifuged
at 1000 x g at room temperature for 5 minutes; the supernatant was then
removed by aspiration. 10% NCS/DMEMcontaining 10% (v/v) glycerol was
equilibrated in 10%C02 for 1 hour, and the cell pellet was resuspended in Irnl
of this medium. Aliquots of the suspension were put into cryotubes, packed in
cotton wool and frozen overnight at -80°C. The tubes were then transferred
to liquid N2 for long term storage.
2.3.6 Resurrection of frozen cell stocks from liquid nitrogen
The cryotube containing the cells was removed from liquid nitrogen and
placed in a 37°Cwater bath. The tube was then transferred to the cell culture
sterile flow hood where the cells were titurated gently with a sterile Pasteur
pipette to disperse any large aggregates of cells. The 3T3-Ll fibroblasts were
seeded onto 1Ocm.2ce1l culture plates containing 10% (v/v) NCS/DMEM
medium. The ce1ls were then maintained in an incubator at 3TC in an
atmosphere of 10%C02.
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2.3.7 Insulin-stimulated 2-deoxy-D-glucose uptake in 3T3-L1
adipocytes
Uptake of 2-deoxy-D-glucosewas measured using the method of Gibbs et al.
(1988) and Frost and Lane(1985).
In all experiments cells were used between 8 and 13 days post differentiation.
For transport assays 3T3-Ll adipocytes grown on 6-well plates were used.
Prior to assay, cells were incubated in serum-free Dulbecco's Modified Eagles
Medium for 3 hours prior to use. The cell monolayer in each well was washed
three times in 3ml of KRPbuffer (see section 2.2.2) at 37°Cand then incubated
on a hot plate at 37°C in 9S0J11of KRP. Insulin was added at the required
concentration for the time indicated in the figures and tables.
The uptake of the sugar was initiated by the addition of 50ltl of [3H]2-deoxy-D-
glucose to a final concentration of 100ItMand O.S"Ci/ml. The reaction was
terminated 3 minutes later by rapidly decanting the KRPbuffer, (containing
the 2-deoxy-D-glucose) and immediately immersing the 6-well plate
sequentially into 3 beakers containing ice-cold PBS(see section 2.2.2 for PBS
details). After air-drying the plates, 1ml of 1% Triton X-lOOin water was
added to each well and the plates were left shaking for 1 hour. The cell
associated radioactivity was measured by scintillation counting. To determine
the specific uptake of 2-deoxy-D-glucose, the inhibitor cytochalasin B, was
added to three of the 6-wellsin each plate containing the KRPand insulin, at
a concentration of 10J1M,at the beginning of each assay.
The radioactivity associated with the wells in the presence of cytochalasin B
is taken as a measurement of non-specific deoxy-glucose association with the
monolayer. This value was subtracted from counts obtained in the abscence
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of cytochalasin Bto provide a figure which was used to calculate the specific
transport rate.
It has been calculated from experiments in this lab and others that one well
of a 6-well plate contains 2.1 million cells and as a result the rate of 2-deoxy-
D-glucose transport is expressed as pmol/min/million cells which is the
standard unit used within the field of glucose transport.
2.3.8 Hormonal treatment of 3T3-Ll adipocytes
48 hours prior to the assaying the insulin-stimulated 2-deoxy-D-glucose
uptake, the adipocytes were fed with 10% (v/v) FCS/DMEMcontaining the
concentration of steroid hormone indicated in the figures and tables
presented in subsequent chapters. All other procedures involved in the assay
are exactly as described in section 2.3.7.
2.4 Protein Concentration Assays
2.4.1 Lowry method of protein concentration determination
The protein concentration of the membranes in the studies presented were
assayed after trichloroacetic acid precipitation [Lowryet al., (1951); Peterson,
(1977)]. The volume of each protein sample was brought to 1ml using distilled
water, and 100J'1of 0.15% (w/v) sodium deoxycholate was added to each tube.
The contents of each tube were mixed, and incubated at room temperature for
10 minutes. After addition of 100J'1of 72% (w/v) trichloroacetic acid the
contents of each tube were mixed again, then centrifuged at 3000 x g for 15
minutes at 4°C and the precipitates collected. The supernatants were
discarded and the precitates air dried. The pellets were resuspended in 200J'1
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of distilled water and 1ml of Reagent A (Section 2.2.2) added, the contents of
each tube mixed, then incubated at room temperature for 10 minutes. O.5mlof
Reagent B (Section 2.2.2) was added, the contents of each tube mixed and the
absorbance (A7S0) measured after a 30 minutes incubation at room
temperature.
The concentration of the sample proteins were determined from a standard
curve (0 to 200J,lg)constructed from 1mg/ml BSAand treated in the same
manner as the protein samples of unknown concentration
2.4.2 Quantigold Protein Determination
This method was used to determine the protein concentrations of sub-
fractionated muscle preparations from individual animals, where
concentrations were very low and samples at a premium.
Using BSAas a standard, 10,,1 of sample was added to 1ml of Quantigold
solution, mixed, and incubated at 37·e for up to one hour in a plastic cuvette.
The absorbance was then read in a spectrophotometer at S9Snm. The protein
concentration was determined after plotting the standard curve of
concentration of BSA against absorbance. This method of protein
determination is accurate to Sng of protein and is linear up to 200ng protein.
2.S SDS/polyacrylamide gel electrophoresis
SOS/polyacrylamide gel electrophoresis was carried out using Bio-Rad mini-
PROTEANII or Hoefer large gel apparatus.
The Bio-Rad mini-PROTEAN II slab gels had a stacking gel of 2cm and the
Hoefer stacking gel was Scm. The stacking gel was composed of S%
acrylamide/0.136% bisacrylamide in 12SmM Tris-HCI, (pH 6.8), 0.1% SOS,
polymerised with 0.1% (w/v) ammonium persulphate and 0.05% N, N, N', N'-
tetramethylethylenediamine (TEMEO).
The separating gel consisted of 10% acrylamide/0.28% bisacrylamide in
0.383mM Tris-HCI, (pH 8.8), 0.1% SOS and polymerised with 0.1% (w/v)
ammonium per sulphate and 0.019% N, N, N', N'-tetramethylethylenediamine
(TEMEO).
The protein samples were solubilised in sample buffer (see section 2.2.3) and
loaded onto the wells in the stacking gel. The gel was then immersed in
electrode buffer (see section 2.2.3) and the gel electrophoresed until the
tracking dye had migrated to the bottom of the gel. For Bio-Rad mini-
PROTEANgel a constant voltage of 150 volts for 90 minutes ensured adequate
separation of the pre-stained SOS/PAGE markers. Large gels were
electrophoresed overnight at 60-70 volts in a Hoefer gel tank.
2.6 Western blotting of proteins
After separation of the proteins by SOS/PAGEas described in section 2.5, the
gels were removed from the plates and equilibrated in blot buffer (see section
2.2.5) at room temperature for 30 minutes. Each gel was then placed on top of
a piece of nitrocellulose paper (O.4S~m pore size) which had been cut to the
size of the gel and pre-soaked in blot buffer. This was then "sandwiched"
between 2 layers of 3mm filter paper which had also been pre-soaked with
blot buffer. The sandwich was then placed in a cassette and transfer of the
proteins onto the nitrocellulose was performed using either a Bio-Rad trans-
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blot tank, for large gels, or the Bio-Rad mini trans-blot tank for the mini-
gels.
Transfer was achieved at a constant current of 250mA for 3 hours at room
temperature. The nitrocellulose membranes were then removed and the
efficiency of transfer was determined by staining the nitrocellulose with
Ponceau S solution prior to blocking.
2.6.1 Immunodetection of GLUT-Ion nitrocellulose membranes
Toblock non-specific binding sites on the nitrocellulose, the membrane was
shaken in 3% (w/v)BSA/1st wash buffer (see section 2.2.5) for 1 hour. The
nitrocellulose was then placed into 3% (w/v)BSA/lst wash buffer containing
the GLUT-1antibody at a concentration of 10"g/ml and incubated overnight
at room temperature on an orbital shaking platform. Following this, the
nitrocellulose was washed five times at 10 minute intervals with 1st wash
buffer, and a further three times in 2nd wash buffer (see section 2.2.5) at the
same interval. The membrane was then placed in 3% (w/v)BSA/1st wash
buffer containing 12SI-Iabelled goat anti-rabbit IgG (1",Cil20ml) for 3 hours.
Mer this the nitrocellulose was the washed as before and dried between two
sheets of cellophane. Finally the nitrocellulose was exposed to KodakX-0matS
film in an autoradiography cassette for up to 48 hours before being developed
using an X-0mat processor.
2.6.2 Immunodetection of GLUT-2, 3 & 4 on nitrocellulose
membranes
The non-specific binding sites on the nitrocellulose membrane were blocked
by shaking for 1 hour in 5% (w/v) non-fat milk/1st wash buffer. The
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membrane was then transferred into 1% (w/v) non-fat milk/1st wash buffer
containing affinity-purified antibody at lOug/ml or serum at a 1 : 200 dilution
and incubated overnight at room temperature on an orbital shaking
platform. The nitrocellulose was then washed five times in 1st wash buffer
followed by three times in 2nd wash buffer with 10 minutes between each
wash. After this the membrane was incubated in 1% non-fat milk/1st wash
buffer containing either 12SI-Iabelled goat anti-rabbit IgG (1!lCil20m1)or
HRP-linkedgoat anti-rabbit IgG(1 : 10000) for 3 hours or 1 hour respectively.
If the 12SI-Iabelled IgG method was used then the blot was washed and
developed as in section 2.6.1.
However if the second antibody used was HRP-linked goat anti-rabbit IgG,
after washing as before the membrane was submerged in a solution
containing equal volumes of Amersham "detection reagent 1" and "detection
reagent 2" for 1 minute. The nitrocellulose was then removed from the
solution, wrapped in cling-film and exposed to Kodak X-Omat S film and
developed in an X-Omatprocessor.
2.7 Antibody Preparations
2.7.1 Purification of anti-peptide antibodies
A series of peptide columns have been prepared by others which were used to
prepare affmity purified antibody stocks. The protocol for use is as follows.
The column was pre-washed with 10ml of 2SmMsodium phosphate, (pH 6.5).
S.Sml of anti-GLUTpeptide rabbit serum, was mixed with O.5ml of 2SOmM
sodiumphosphate (pH6.5) and added to the column, allowed to run through it
by gravity, and subsequently passed through the column 4 more times. The
column was then washed with 2SmM sodium phosphate (pH 6.5) until the
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eluant gave an OD2SOnmreading of less than 0.1. The column was then
allowed to almost run dry before the bound IgGwas eluted by the addition of
IOmlof O.lMglycine, (pH 2.4).
The eluant was collected in 1ml fractions and the OD2SOnmreadings were
taken for each fraction. The fractions with the highest OD2SOnmwere pooled
and 100~1of O.SMTris (pH 6.S) was added to neutralise the pool. The pooled
sample was dialysed against PBS, (pH 7.4) overnight at 4°C. Finally the
dialysed samples were then aliquoted into 1.Sml microfuge tubes, snap frozen
and stored at -SO°Cuntil use.
2.8 Animal upkeep, feeding and blood pressure
monitoring
2.8.1 Milan rat upkeep
Male Milan rats (body weight 2S0g) were purchased from ltie University of
Sheffield Field Laboratory (Sheffield, United Kingdom). Animals were housed
in the Joint Animal Facility, at the University of Glasgow,on a 12h day/night
cycle with unrestricted access to water and standard laboratory chow. 24
hours after delivery of a group of animals, blood pressure measurements
were made using tail-cuff plethysmography [Evans et al. (1993)]. This
procedure was carried out on our behalf by the staff at the Joint Animal
Facility. All other strains of rat mentioned in the study were part of a
controlled breeding programme by the animal house at the Western
Infirmary (Glasgow) and the animals were subject to the same conditions
mentioned above. Aspects of these species will be discussed in subsequent
chapters.
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2.8.2 SHRSP F2 upkeep
The animals were housed in the animal facility at the Western Infirmary. All
rats were housed in conditions of temperature (21°C)and a 12 hour day/night
cycle (7 am to 7 pm)and maintained on normal rat chow and water ad libitum.
2.9 Hindlimb skeletal muscle dissection and sub-cellular
fractionation
The method of Klip et al., (1987) was used in the preparation and sub-cellular
fractionation of hindlimb skeletal muscle membranes. The animals were
sacrificed by cervical dislocation and the hindlimb muscle was dissected. All
subsequent procedures were carried out on ice or at 4°C. The skeletal muscle
was minced and diluted 19/10ml in muscle buffer (see section 2.2.6) before
being homogenised in a Polytron PT20 for 1 minute at setting 4-5. The
homogenate was then centrifuged at 1,200x g for 10 minutes. The pellet was
re-homogenised exactly as above and the centrifugation repeated. The
supernatants from both steps were pooled before being further centrifuged
at 9000 xg for 10 minutes. The pellet was discarded and the supernatant was
centrifuged at 190000 x g for 60 minutes. The pellet from this latest step
contained the "crude membranes" which were subsequently hand
homogenised for 20 strokes in 1ml of muscle buffer.
The crude membrane fraction was then applied to a discontinuous sucrose
gradient of 25%,30%and 35% (w/v) sucrose and centrifuged at 150,000 x g for
16 hours at 4°C. The 25% (w/v) sucrose fraction contained the purified
plasma membranes and the 35% (w/v) sucrose fraction contained the
intracellular membranes. These fractions were collected, diluted 5-fold in
muscle buffer then further centrifuged at 190,000 x g for 60 minutes to wash
6S
out the sucrose. The pellets from the plasma membrane and intracellular
membrane fractions were then resuspended and homogenised in 100!,1of
muscle buffer before being snap-frozen in liquid nitrogen and stored at -80oe
until use.
2.10 Dissection and "crude membrane" preparation of
liver tissue
All the procedures were performed on ice or at 4°Cand in accordance with
the method of Arion et al., (1984). The liver was dissected from the animal
which had been sacrificed by cervical dislocation. The tissue was weighed
and placed in a beaker with SHbuffer (see section 2.2.8) at 10 ml per gram of
tissue. Next the liver was homogenised with 20 strokes in a motorised 30ml
teflon homogeniser, clearance O.4mm. The homogenate was centrifuged at
10000 x g for 15 minutes at 4°C. The pellet from this centrifugation was
resuspended in SH buffer. The pellet was then homogenised, snap-frozen in
liquid nitrogen and stored at -SO°Cuntil use. This fraction contains
approximately 80%of the liver S' nucleotidase activity and was therefore used
as an crude membrane fraction in subsequent studies.
2.11 Dissection and sub-cellular fractionation of
adipocyte tissue
The epididymal fat pads were removed from male rats which had been
sacrificed by cervical dislocation. All subsequent steps in the procedure
followan amended protocol from Simpson et al. (1991). The tissue was rinsed
in KRHbuffer, pH7.4, containing 1%(w/v) BSAat 37°e before being minced
through a plastic tea strainer into a lOOmlsUiconised flask containing 10 ml
KRH/BSA, 20mg collagenase and Smg trypsin inhibitor. The flask was
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incubated at 3TC with continuous gassing with nitrogen and gentle agitation
for 1 hour. The contents of the flask were again filtered through a tea
strainer and washed in KRHbuffer pH 7.4, containing 1%(w/v) BSAat 37°C.
The solution was centrifuged at 10000 x g for 1 minute to compact the
adipocytes which float, and all the buffer below the cells was removed using a
20ml syringe and needle. This procedure was repeated twice more to obtain a
pure cell suspension. The cells were resuspended in KRHbuffer, (pH 7.4),
containing 3%(w/v) BSAbefore being homogenised by 20 up and down
strokes of a hand-held homogeniser. The homogenate was centrifuged in an
SS34rotor for 15minutes at 16000 x g at 4°Cand the pellets were resuspended
in 1ml of KRH buffer (pH 7.4). This pellet represents a crude plasma
membrane preparation which was homogenised, snap-frozen in liquid
nitrogen and stored at -80·Cuntil use.
The supernatant from the first spin was further centrifuged at 41000 x g at
4·C for 15 minutes. The pellet from this spin contained the "Heavy
Microsomes" which were resuspended in 1ml of KRH buffer, (pH 7.4),
homogenised, snap-frozen in liquid nitrogen and stored at -80·C until use.
The supernatant from the previous spin was transferred to a clean tube and
centrifuged at 100000 x g for 75 minutes at 4·C. After this, the pellets were
resuspended in 2ml KRHbuffer, (pH 7.4), homogenised and re-centrifuged at
l00000xg for another 75 minutes at 4·C. The pellet from this step contained
the "Light Microsomes" which were resuspended in 1ml KRH buffer,
homogenised, snap-frozen in liquid nitrogen and stored at -80°Cuntil use.
2.12 Brain region dissection and membrane preparation
Brain regions were individually dissected as described in Brant et al. (1993).
The regions from four rats were combined and homogenised in ice-cold 5 mM
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sodium phosphate, (pH 7.4), 150 mM NaCIas described Brant et al. (1993). A
membrane pellet was obtained by centrifugation at 100000 x g for 1 hour. The
membranes were washed and aliquoted before being snap frozen and stored at
-80°Cprior to use.
2.13 Si-Nucleotidase assay
5' Nucleotidase is a marker enzyme for plasma membranes and was used to
determine the distribution of the plasma membrane fraction in the procedure
above. An aliquot of the membrane fraction was added to buffer A to a final
volume of lml in the presence of 0.3% (v/v) Triton-X-lOO,S.OmM2'3'-AMP,
0.2mM S'-AMPand 2.0mM (2"Ci) [3H]S'-AMP. The solution was mixed and
incubated at 37°C. Duplicate 100,,1aliquots were removed at 0, 10,20, 30,60
and 90 minutes after addition of membranes. Immediately after removal, 50,,1
0.25M zinc sulphate was added and the tube vortexed. 100,,10.12SM barium
chloride was then added and the sample was again vortexed. The samples
were incubated on ice for 10 minutes then centrifuged in a microfuge at
14500 x g for 5 minutes. Duplicate 100,,1aliquots of the supernatant were
removed and counted.
The supernatant contains the product of the Sf nucleotidase and the slope of
product/time used to calculate rates as mole product/hour/mg protein in
duplicate assays.
2.14 Statistical analysls
Results presented in this thesis were subject to statistical analysis using the
StatViewPackage on a Macintosh computer. Unless stated the student's T-test
in the model used.
Chapter 3
Analysis of the glucose transporter complement of
metabolically important tissues from the Milan
hypertensive rat.
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3.1 Aims
The aims of this chapter are:
1. To examine the glucose transporter complement of muscle and fat of
the mildly hypertensive Milan rat compared to the isogenic
normotensive control strain.
2. To examine changes in the expression of GLUT-2in liver of the Milan
hypertensive rat compared to the normotensive control, and to also
examine the activity of glucokinase and glucose-6-phosphatase in
this tissue.
3. To study the glucose transporter distribution in selected brain
regions of these animals.
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3.2 Introduction
The inability of peripheral tissues to respond to insulin has been identified in
a number of clinical conditions, many of which are associated with an
increase in blood pressure, these include ageing, obesity and non-insulin
dependent diabetes mellitus (Type II diabetes) [Ferrani et al. (1987); Natali et
al. (1991)]. Insulin resistance has also been reported in several model
systems for hypertension, including the spontaneously hypertensive rat
(SHR) and Milan rat. The insulin resistance associated with essential
hypertension may be subtly different from that observed in obesity or type II
diabetes in that it is confined mainly to peripheral tissues, and is limited to
non-oxidative pathways of intracellular glucose utilisation [Ferrani et al.
1987;Ferrani&Weidmann (1990);Nataliet al. (1991)J.
Dall'Aglioet al. (1991) flrst demonstrated the abnormalities in insulin and
lipid metabolism in the normotensive and hypertensive Milan rat strains
which were generated by Professor G. Bianchi in his laboratory in Milan.
These two rat strains are genetically related and have been developed from
the same Wistar stock colony with some cross-mating between the rats of
these two strains during the first two generations. [Bianchi et al. (1984). In
the study by Dall'Aglioet al. (1991) the rats were sacrificed by decapitation
and bloodwas collected for analysis. The blood was subsequently assayed for
glucose, insulin, triglyceride and total cholesterol. The Milan hypertensive
rat strain was shown to have elevated blood pressure, with a mean blood
pressure of 118mm Hg, compared to 9Smm Hg for the normotensive strain.
Furthermore the hypertensive rat is hyperinsulinaemic and
hypertriglyceridaemic. However both the normotensive and hypertensive
strains had the same circulating glucose concentration. Dall'Aglioproposed
that the association of hypertension, hyperinsulinaemia and
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hypertriglyceridaemia demonstrate a defect in the ability of insulin to
stimulate glucose uptake. The compensatory hyperinsulinaemia results in
the increase of both blood pressure and plasma triglyceride concentration.
This theory is substantiated by Reaven et al. (1991) in a study examining
insulin-stimulated glucose transport in adipocytes from SHRand WKYrats.
The adipocytes from the SHRrat were shown to be insulin resistant compared
to those from the normotensive WKYrat strain. Furthermore, the greater
the defect in insulin action, the higher the plasma insulin concentration, the
plasma triglyceride concentration, and the blood pressure.
The development of insulin resistance in both type I and type II diabetes has
been extensively studied in both human and rodent models of the disease. It
has been well established that defects in the glucose transport systems
present in either peripheral tissues or the pancreatic f3-cellsare potentially
important in both the onset and development of the disease [Gould & Bell
(1990);Bellet al., (1990)]. Glucose transport across the plasma membranes of
animal cells is mediated by a family of glucose transporter proteins of the
facilitative diffusion type. Within the context of diabetes, the most important
transporter would appear to be the so-called insulin-responsive glucose
transporter, GLUT-4. This transporter is expressed in adipose tissue, muscle
and heart; tissues which exhibit an acute increase in their rates of glucose
transport within minutes of exposure to insulin. This increase is mediated by
the movement of a pool of GLUT-4from an intracellular location to the plasma
membrane; a process termed translocation. Defects in the level of expression,
function and/or targeting of GLUT-4have been reported associated with
insulin resistant states [Gould & Holman (1993); Shepherd & Kahn (1993);
James & Piper (1994); Garvey et al. (1989); Kahn & Flier (1990); Pedersen et al.
(1990)]. Hence, it will be of interest to examine changes in the pattern of
expression of this and other transporter isoforms in models of hypertension.
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Here, a panel of immunological reagents have been used to determine the
relative levels of the glucose transporter isoforms expressed in adipose tissue,
muscle and liver, together with several brain regions in the hypertensive
Milan rat compared to its control normotensive relative. This study has
shown that there are profound decreases in the level of GLUT-4 in the
intracellular membranes of skeletal muscle from hypertensive animals. This
may play a key role in the observed insulin resistance in this species. In
addition, several potentially important changes have been observed in brain
regions from the hypertensive animals. These results suggest that defects in
glucose transporter expression may participate in the observed insulin
resistant states associated with hypertension.
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3.3 Methods
3.3.1 Animals
Male Milan rats (body weight -250g) were purchased from the University of
Sheffield Field laboratory (Sheffield, United Kingdom). Animals were housed
on a 12h day/night cycle with unrestricted access to water and standard
laboratory chow. 24 hours post delivery of a group of animals, blood pressure
measurements were made using tail-cuff plethysmography [Evans et al.
(1993)]; the characteristics of the animals used in this study are outlined in
Table 3.1. Blood pressure measurements were made on each animal while
conscious; five recordings were obtained from each animal and the average
value calculated. The mean blood pressure of the animals within each of four
groups analysed are presented (Table 3.1). Animals were sacrificed the
following morning, and individual tissues immediately dissected and
maintained on ice. In all cases, homogenisation and subcellular fractionation
of the individual tissues according to the protocols outlined in Chapter 2 was
undertaken within 1 hour of sacrifice.
3.3.2 Glucose-6-phosphatase assay reagents
Glucose-6-phosphate (monosodium salt), potassium pyrophosphate, mannose-
6-phosphate (disodium salt) and Histone 2A were all obtained from Sigma
Chemical Co., Poole, UK.The following solutions were prepared:
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Substrate stock solutions:
Glucose-6-phosphate (monosodium salt), 0.3 M stock
Mannose-6-phosphate (monosodium salt), 12.5 mM stock
Both of the above solutions were adjusted to pH 6.5
Histone, 10 mg/rnl,
0.1 MHEPES,4.776g in 200ml HzO,pH6.5.
0.1 MEDTA,3.72g in 100mlH20,pH6.S.
Stopping reagent. (Made fresh daily.)
6 parts 0.42%Ammonium molybdate/O.SMH2ID4-
2 parts 10%SDS.
1 partdH2Q
The assay measured phosphate produced, with determination by 4
micromodifications of the Ames method (Ames 1966) where the reaction of
inorganic phosphate with ammonium molybdate and sulphuric acid produces
a phosphomolybdate complex. The absorbance of this at 820 nm is
proportional to the amount of inorganic phosphate produced. The
absorbance is related to the amount of phosphate released using a standard
curve constructed using stock inorganic phosphate. One unit of activity
represents 1 mmol of phosphate released/min.
3.3.3 Glucose-6-Phosphatase assay
Glucose-6-phosphatase activity was measured in a 100!,1final reaction volume
in disposable plastic tubes, in order to eliminate the possibility of trace
phosphate contamination from glass tubes washed in detergents. Final
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concentrations were 20 mM HEPES,2.5 mM EDTA and final glucose-6-
phosphate concentrations of 1, 1.4, 2, 2.6, 5 and 30 mM for kinetic analysis.
The reaction was initiated by addition of 20111of appropriately diluted
microsomes in Sucrose-HEPESbuffer to 80111of substrate at 30·C. The assay
was performed in duplicate. Disruption of microsomal vesicles was carried
out by inclusion of 10 mg/rnl Histone 2A in the assay (Blair and Burchell,
1988). Substrate without the inclusion of any microsomes was termed 'blank'
and was a measure of any free, non-specific inorganic phosphate which may
naturally be present in the assay. After a 10 minute period the reaction was
stopped by addition of 900111stopping reagent. 20111of the diluted microsomes
was then added to the 'blank' tube. The assay was then placed in a 42·Cwater
bath for 20 minutes to allow full colour development.
The assay was measured at 820 nm on a Phillips PU8670spectrophotometer.
3.3.4 Pyrophosphatase assay
Pyrophosphatase activity was measured as described above using HEPES
adjusted to pH 6.0 and potassium pyrophosphate as the substrate. The final
concentration of pyrophosphate used was 0.5, 1, 1.4, 2,2.6 and 5 mM. Colour
was allowed to develop for 10 minutes at 30·C prior to measurement of the
absorbance at 820 run.
3.3.5 Mannose-6-phosphatase assay
One unique feature of glucose-6-phosphatase is that it is situated with its
active site inside the lumen of the endoplasmic reticulum, whereas all the
other enzymes involved in gluconeogenesis and glycogenolysis are
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elsewhere in the cell. This means that for glucose-6-phosphatase activity in
vivo, in addition to the glucose-6-phosphatase enzyme itself, it is also
necessary to allow the substrates and products of the enzyme to cross the
endoplasmic reticulum membrane.
Untreated microsomes are heterogeneous preparations composed of (a) intact
vesicles (intact microsomes) in which the membrane acts as a selective
permeability barrier, and (b) disrupted structures in which selective
permeability is lacking and the enzyme has free access to ionic substrates and
inhibitors.
When glucose-6-phosphatase activity is assayed in microsomal samples in the
test-tube, the enzyme appears more active in disrupted microsomal vesicles
than in intact microsomes as the active site has unrestricted access to the
substrate. The enzyme activity is therefore described as latent. Latency may
be expressed as the percentage of the enzyme activity of fully disrupted
microsomes that is not expressed in untreated microsomes. In other words,
latency is a measure of the intactness of the microsomes.
The proportion of the two forms (intact and disrupted) may be quantified by
assays of the low Km mannose-6-phosphatase activity that is expressed only
in disrupted Structures (Arion et al, 1976). Therefore the latency of the
enzyme in the disrupted component of untreated microsomes can be
calculated using the following equation:
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Where 1M,UM and DM added to the reaction velocity (V) or mannose-6-
phosphatase activity (M) represent the values for intact, untreated and
disrupted microsomes respectively.
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3.3.6 Glucokinase and Hexokinase assays
Hexokinase and glucokinase were determined by the method of Agius and
Tosh (1990). Hexokinase and glucokinase were determined in the cytosolic
fractions of rat liver samples. The following reagents were prepared:
Medium 100mMKCl 1.0ml
SOmMHEPFS 0.5 ml
7.5 mMMgCl2 0.75 ml
ImMEDTA O.lml
SmM(DTT) O.SOm!
Dithiothreitol
7.15 ml of H20 was added and the pH of the solution adjusted to 7.4.
Main Reagent l00mMKCl 2ml
SOmMHEPES 1ml
l00mMEDTA 0.2ml
7.5 mM MgC12 1.5m!
0.5 mMNAD* loOmI
SmMDTT 1.0m!
G6PDH(1 U/ml) 2Ol-l1
6.7m!
*Nicotinamide adenine dinucleotide.
The preparation of the main reagent was based on the method of Davidson and
Arion (1987). The volume was made up to 20 ml.
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Starting reagent: 2.5 mM adenosine triphosphate (ATP).
Main reagent --- 10ml + 0.5 mM glucose
Main reagent --- 10ml + 100 mM glucose
The supernatant fraction was diluted (1:3) in the medium as detailed above.
The reactions were then started by the addition of ATP. Blanks without cell
extract were run for each cocktail (low and high glucose, with or without
ATP). Sample blanks contained cell extracts and complete cocktail except for
ATP. Sample blanks (without ATP) were subtracted for both high and low
glucose concentrations. Glucokinase activity was determined from the
difference in corrected rates between 100 mM and 0.5 mM glucose.
The assays were performed at 30°Cusing a Cobas Fara analyser (Department
of Clinical Biochemistry, University of Dundee Ninewells Hospital and Medical
School) and rates were determined by a linear search and regression using a
PCdirectly coupled to the analyser for this purpose.
3.4 Results
3.4.1 Subcellular fractionation of skeletal muscle
Wewished to examine the relative levels of GLUT-4in skeletal muscle from
Milan rats. A subcellular fractionation procedure employing sucrose
gradient centrifugation has been published which described a method for the
preparation of plasma membranes and intracellular membranes enriched for
insulin-responsive glucose transporters [Klip er el., (1987)]. Our first
objective was to establish that this procedure was appropriate and
reproducible for the Milan rat strain to be employed. To establish this, 5 I
nucleotidase activity was assayed as it is a well established plasma membrane
marker. The fractions obtained from the sucrose gradient were analysed and
COnfirmedthe results of [Klip er al., (1987)], in that the 25% sucrose fraction
(proposed to be enriched in plasma membranes) was greatly enriched in 5'
nucleotidase activity, and the 35% fraction (which contains the insulin-
sensitive glucose transporter pool) exhibited no enrichment of activity (Table
3.2). At the time of this work, there were no suitable markers for the
intracellular membrane fraction; however, as shown below, the intracellular
fraction does contain the majority of the GLUT-4, suggesting that the
fractionation procedure is appropriate.
Two further sets of control experiments were performed. We assayed the
protein content of the fractions from the sucrose gradients prepared from
normotensive and hypertensive animals. As shown in Table 3.2, no
significant changes in protein content were observed when comparing the
two strains. Similarly, these two strains showed identical subcellular
distribution of 5I nucleotidase activity, further suggesting that the
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Table 3.1
Characteristics of animals.
Body weight (g)
Group No: 1 2 3 4
Normotensive
Hypertensive
243±9
2S1±9
255±12
245±7
n.d.
n.d
238±10
246±8
Normotensive
Hypertensive
Blood pressure (mmHg)
133±7 n.d. 137±S
164±4* n.d. 168±3*
138±4
163±9*
All experiments were performed on four separate groups of littermates,
purchased over a twelve month period. Within each group, 4 normo- or 4
hypertensive Milan rats from the same litter were analysed coincidentally.
Blood pressure measurements were performed on each rat using
plethysmography as described in section 2.8, and an average value of 5
determinations for each rat was obtained. Values above are mean ± s.d. (n=4)
of the average values for each animal within each group (1 - 4). *Indicates a
statistically significant difference between normo- and hypertensive animals
Within the given group (p<O.OS). n.d ....not determined.
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Table 3.2
Subcellular fractionation of skeletal muscle from
normo- and hypertensive Milan rats.
(IJ g)
MNS MHS
5' Nucleotidase activity
(nmollmg/h)
MNS MHS
Protein
Fraction
Total membranes n.d. n.d. 35 ± 6 38 ± 8
25%
30%
35%
612 ± 20
1013 ± SS
1587 ± 255
523 ± 25
1003 ± 135
1700 ± 215
221.5 ± 23
105.3 ± 14
30.3 ± 4.5
238.5 ± 41
107.4 ± 12
20.5 ± 6.7
Shown above are data from a representative group of animals, purchased at
the same time. Each value is the mean ± s.d. of at least triplicate
determinations. MHS = Milan hypertensive strain and MNS = Milan
normotensive strain.
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subcellular fractionation procedure produced consistent fractions when
applied to the two animal strains used.
We therefore measured GLUT-4levels in the plasma membrane fraction (25%
sucrose) and intracellular membrane fractions (35% sucrose). No significant
changes were observed in the plasma membrane GLUT-4content of normo-
and hypertensive animals (Fig. 3.1); note that the small increase in plasma
membrane GLUT-4content is not significant, as determined using Students t-
test. In contrast, a significant reduction in the level of GLUT-4in the 35%
sucrose fraction (corresponding to the intracellular, insulin-responstve
GLUT-4pool) was consistently observed in the hypertensive group [53 ± 4%,
n=4, p<O.Ol](see Fig.3.1 panels A & B). These results are unlikely to be an
artefact of different subcellular fraction profiles from the normotensive and
hypertensive animals, as (I) the protein recoveries were similar in each
fraction from both normo- and hypertensive animals (Table 3.2), (il) SDS-
PAGEanalysis indicated no gross change in polypeptide composition of the
intracellular membrane fraction between norrno- and hypertensive
preparations (data not shown), and (iii) the relative recoveries and
enrichments of the plasma membrane marker enzyme 5' nucleotidase were
unchanged between the two groups (see Table 3.2). The reduction in GLUT-4
levels was observed in four independent groups of animals, and the data from
the four sets is presented graphically in Fig. 3.1 panel B. Note that the levels
of GLUT-4observed in the plasma membrane represent about 5% of the total
levels of GLUT-4in muscle membranes. Thus, the statistically insignificant
increase in GLUT-4levels in the plasma membrane fraction cannot account
for the large decrease in the intracellular membrane fraction observed in
the hypertensive animals.
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Figure 3.1a
Skeletal muscle GLUT-4 levels in Milan norrno-
and hypertensive rats.
Shown is a representative immunoblot of sucrose gradient fractions of
skeletal muscle membranes. Fractions from the 25%, 30% and 35% w/v
sucrose fractions were analysed from groups of normo- (N) or hypertensive
(H) Milan rats. 2S!lg of membrane protein were electrophoresed on 10% gels,
prior to transfer to nitrocellulose membranes as described in section 2.6.
Immunoblots were developed with anti-GLUT-4 antibodies exactly as described
[Brant et al. (1993)], the position of the SOkDa molecular weight marker is
indicated.
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Relative levels of GLUT-4 in sub-cellular fractions of
Figure 3.1 b
skeletal muscle fron the Milan rat.
25 3530
Sucrose Gradient Fraction (%)
Skeletal muscle GLUT-4 levels in Milan normo- and
hypertensive rats.
Shown is a comparison of the GLUT-4levels in normotensive (stippled boxes)
and hypertensive (solid boxes) Milan rat muscle membrane fractions. Data is
presented as the mean ± s.d. of 4 independent groups of animals, in each case
the normotensive values for each fraction have been set at 100%for purposes
of comparison. * indicates statistically significant differences, p-D.O'l. The
percentage distribution of levels of GLUT-4in these fractions were: 25%
fraction 6.5% total GLUT-4,30% fraction 14.6%total GLUT-4,35%fraction 74%
total GLUT-4(mean values of four normotensive animals).
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Levels of GLUT-l in subcellular fractions were, in our hands, too low to
reliably quantitate (data not shown).
3.4.2 Subcellular fractionation of Adipocytes
Wehave analysed the glucose transporter content of adipocytes of the Milan
hypertensive rat compared to the isogenic control strain, as adipocytes
constitute the other major site of peripheral glucose disposal. Surprisingly,
we observed no significant change in the total level of GLUT-4protein in
adipocytes from the hypertensive animals compared to controls as seen in
Fig.3.2.
Analysis of GLUT-l levels in adipocytes was also performed. However we
observed very low levels of GLUT-l expression in these cells, with no change
apparent between hypertensive and normotensive animals (not shown). The
low level of expression of GLUT-l in adipocytes is consistent with previous
studies from this and other laboratories [Gould & Holman (1993); Baldwin
(1993)].
3.4.3. GLUT-2 expression in liver
Glucose transport in hepatocytes is mediated via the GLUT-2isoform [Gould&
Bell (1990)]. Since GLUT-2 is predominantly expressed at the plasma
membrane, we employed the method cited in section 2.10 to prepare of
hepatocyte plasma membranes for immunological analysis. Figure 3.3 is a
representative immunoblot which demonstrates that there is no significant
change in hepatic GLUT-2expression in the hypertensive state compared to
the normotensive control group.
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Figure 3.3
GLUT-2 expression in hepatocyte plasma membranes.
25f1gof plasma membranes isolated from liver homogenates were subject to
electrophoresis and immunoblotting as described in the materials and
methods section. Membranes from two groups of normotensive (N) and
hypertensive (H) rats are presented for comparison. The blots were probed
with antiserum against the liver-type glucose transporter, GLUT-2,and the
entire running gel is shown.
Glut 2
N H N H
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3.4.4. Glucokinase and glucose-6-phosphatase levels in liver
3.4.4.1 Glucokinase
Glucokinase (GK)is an isozyme of hexokinase that is expressed in the insulin-
secreting pancreatic fS-cellsand hepatocytes. GK catalyses the high-Km
phosphorylation of glucose, functions as the proximal and rate-limiting step
in the utilisation of glucose and plays a crucial role in regulating the
secretion of insulin by pancreatic fS-cells. Therefore GKplays an important
role in the metabolism of glucose in the liver. This enzyme may be a potential
site at which defects in sub-cellular glucose metabolism may be dysregulated
in diseased states such as diabetes. Indeed, defective glucokinase activity and
expression have been identified in some cases of diabetes, notably Maturity
Onset Diabetes of the Young (MODY).We assayed glucokinase activity in the
soluble protein fraction of hepatocytes from normotensive and hypertensive
rats. The results of this analysis although preliminary suggest that there is
no difference in glucokinase activtiy between the hypertensive strain and its
normotensive counterpart. Furthermore, due to the preliminary nature of
these results the data is not included in this thesis.
3.4.4.2 Glucose-6-phosphatase
Glucose-6-phosphatase (Glu-6-Pase) is a key enzyme in the homeostatic
regulation of blood glucose concentration, especially in gluconeogenesis, as it
catalyses the terminal step of this pathway. Glucose-6-phophatase is located
in the lumen of the endoplasmic reticulum, and has been established to be a
mUlticomponent enzyme, with polypeptides involved in the phosphatase
reaction, and polypeptides which catalyse the transport of substrates in and
products out of the endoplasmic reticulum lumen. Liver Glu-b-Pase is
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increased in starved. diabetic and glucocorticoid-treated adrenalectomized
rats. Re-feeding of starved rats and insulin administration to diabetic rats
decreases Glu-6-Pase activity. Defects in glucose-6-phosphatase have been
shown to underlie several other human pathophysiological conditions,
including the glycogen storage diseases. The abberant expression of one or
many of the polypeptides of the glucose-6-phosphatase complex have also
been shown to be responsible for some cases of sudden infant death syndrome
(SIDS)associated with hyper- or hypoglycaemic episodes. Hence, given the
established role of this enzyme in carbohydrate metabolism, we measured the
activity of this enzyme in hepatocyte membranes from normotensive and
hypertensive rats. The assay set-up for measuring the activity is complicated.
In the intact hepatocyte, glucose-6-phosphate has to get into he lumen of the
cell and become de-phosphorylated. Subsequently both the glucose and the
inorganic phosphate have to exit the lumen. If any component in this system
fails the overall activity for G-6-Pase is low. To take that into consideration,
mannose-6-phosphate is used as a substrate,to determine if the mannose-6-
phosphate is active. Another substrate, pyrophosphate (PPi), is used to
determine whether the Pi transporter is functioning. Histone is used to
disrupt the lumen to detemine the activity in intact versus disrupted
hepatocytes. Thus, if there is no activity with mannose-6-phosphate, but ther
is with PPi, then ther is a defect in the glucose-6-phosphate transporter. Also
if activity is measured with mannose-6-phosphate, but not PPi, then the
defect lies in the phosphate transporter. Once again our very preliminary
results indicate that glucose-6-phosphatase activity is normal in both the
normo- and hypertensive Milan rat. Our data is not shown due to the
experiments only being completed once.
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3.4.5. GLUT distribution in brain regions.
Since glucose is the main energy source for brain, we have examined the
relative levels of GLUTs1, 3 and 4 in normotensive and hypertensive rat
brain regions (specifically the frontal cortex, medulla, pituitary,
hypothalamus, thalamus, caudate putamen and hippocampus). The data from
this analysis are presented in Figs. 3.4. (GLUT-I),3.5 (GlUT-3)and 3.6 (GlUT-
4).
In the detection of GLUTs1 and 3 we performed the electrophoresis and
irrununoblotting exactly as described in sections 2.5 and 2.6. Quantitation of
these transporters was made possible by the detection of primary antibody
using [llSI]-goat anti-rabbit, followed by gamma counting of the
nitrocellulose. For the levels of GLUT-4 found in the brain this method
proved insensitive, therefore the primary antibody was detected using the
Eel method which uses an HRP-UnkedIgG.
Analysis of Fig. 3.4 shows that GLUT-l levels are increased in the
hypothalmus and parietal cortex in the hypertensive Milan rat. The
remainder of the regions analysed appear to display no change in GlUT-I
levels. Fig.3.5 displays the amount of GLUT-3detected after gamma counting.
Again, the hypothalamus contains an increased amount of GLUT-3relative to
the normotensive strain. The thalamus also shows an increase with both the
hippocampus and parietal cortex showing a decrease in the GlUT-3 levels. Of
these discoveries the most interesting observation is the change of
transporter level in the hypothalamus.
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Figure 3.4a
Analysis of brain GLUT-1 levels.
A representative immunoblot from 4 independent experiments is presented.
25!-tg of membrane protein from the indicated brain regions were
electrophoresed, transferred to nitrocellulose and the blot developed wi th
anti-GLUT-1 antiserum. (Neriormotenstve animals. Hvhypertenstve animals).
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Figure 3.4b
Relative levels of GLUT-1 expressed in distinct brain
regions of the Milan rat.
4
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Figure 3.4b
Relative levels of GLUT-1 expressed in distinct brain
regions of the Milan rat.
This is a graphical illustration of the level of GLUT-l present in the
immunoblot shown in figure 3.4a, with the mean and S.D. (n=4) for each
region in the normo- (stippled boxes) and hypertensive (solid boxes) animals
shown. Each brain region was adjusted such that the value in the
normotensive group =1. * indicates a statistically significant change, p=O.OS.
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Figure 3.Sa
Analysis of brain GLUT-3 levels.
A representative immunoblot from 4 independent experiments is presented.
25~g of membrane protein from the indicated brain regions were
electrophoresed, transferred to nitrocellulose and the blot developed wi th
anti-GLUT-3 antiserum. (Ns-normorensive animals, H=hypertensive animals).
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Figure 3.Sb
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Relative levels of GLUT-3 expressed in distinct brain
regions of the Milan rat.
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Figure 3.Sb
o
Relative levels of GLUT-3 expressed in distinct brain
regions of the Milan rat.
This is a graphical Illustration of the level of GLUT-3 present in the
immunoblors , typified by figure 3.Sa with the mean and S.D. (n=4) for each
region in the normo- (stippled boxes) and hypertensive (solid boxes) animals
shown. Each region was adjusted such that the value in the normotensive
group =1. * indicates a statistically significant change, p<O.OS.
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Figure 3.6.
Analysis of brain GLUT-4 levels.
2S~lg of cerebellum membrane protein from nor rnotcn sive (~) or
hypertensive (1-1) Milan rat brain was analysed using anti-Cl.I T -4 antiserum
as described. Shown is a representative immunohlot. the position of the SOkDa
molecular weight standard is indicated. !"otl' that thi .. blot was developed
using EeL. In several independen t experiment s, the increase in GLl'T -4 levels
associated with the hypertensive state was -2- to .i-fold (data not shown).
50 kDa
Cerebellum
} Glut 4
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It is known that leptin and NPYare synthesised in the hypothalamus and
both these peptides play a role in energy metabolism. It has also been
postulated the the hypothalamus acts as a "blood glucose sensor", therefore
any change in insulin sensitvity may result in altered expression of the
transporters within the hypothalamus. It must be noted that this is
speculation at the moment and the role of the hypothalamus in overall
glucose homeostasis must be analysed further. As stated previously the levels
of GLUT-4present within the regions of the brain were too low to quantitate
directly but by visual examination of Fig. 3.6 it appears that GLUT-4is
expressed at higher levels in the cerebellum of the hypertensive animal.
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3.5 Discussion
The molecular basis of diminished insulin-stimulated glucose transport
associated with insulin resistance may be the result of depletion of cellular
glucose transporters, mts-rargetting of glucose transporters to a non insulin-
sensitive intracellular location or alternatively may lie on the signalling
pathway from the insulin receptor to the transporter protein [Gould &
Holman (1993); Shepherd & Kahn (1993)]. Hypertension is frequently
accompanied by peripheral insulin resistance, and studies using the
spontaneously hypertensive rat model have indicated that adipocytes from
this species are insulin resistant and exhibit a reduced level of expression of
GLUT-4protein [Reaven et al., (1989)]; similarly, the Milan rat strain is also
known to exhibit insulin resistance [Dall'Aglio et al., (1991)], but to date, no
information of the relative GLUT-4levels in peripheral tissues of this strain
have been reported, and moreover studies of other tissues (notably brain and
liver) have not been performed. Hence, we wished to study the changes in
glucose transporter expression in the Milan hypertensive rat compared to the
normotensive isogenic control strain with a view to determining what, if any,
effects on glucose transporter expression were associated with the
hypertensive state.
3.5.1 Glucose transporter content in peripheral tissues.
Skeletal muscle is the major site of postprandial glucose disposal. We
therefore examined the relative levels of GLUT-4in subcellular fractions of
skeletal muscle from hypertensive rats, and compared the levels to those
observed in control, normotensive animals. We felt it appropriate to
undertake subcellular fractionation of skeletal muscle into plasma membrane
and low density microsomal fractions, since changes in the level of
lOS
expression in the intracellular GLUT-4pool would have profound implications
for insulin-stimulated glucose transport [Shepherd & Kahn (1993); James &
Piper (1994)]. Subcellular fractionation of skeletal muscle membranes was
performed exactly as described in [Klip et al., (1987)]. In skeletal muscle, we
consistently observed a large decrease [53 ± 4%, n=o4,p<O.Ol] in the level of
GLUT-4protein in the low density microsomal fraction of hypertensive
animals compared to age- and weight-matched controls (Fig. 3..1 A& B). Such
a large decrease in the intracellular pool of GLUT-4is likely to have profound
implications for insulin-stimulated glucose transport in these cells, and
suggest that the peripheral insulin-resistance observed by others [Dall'Aglio
et al. (1991)] in the Milan hypertensive rat may be a consequence of
decreased GLUT-4expression.
Interestingly, we observed no changes in adipocyte GLUT-4expression in
these animals. The insulin resistance observed in adipocytes is therefore
likely to be the result of a defect in an as yet unidentified intracellular
signalling pathway, as adipocyte GLUT-4levels are sirrclar in the normo- and
hypertensive states (data not shown). It is unlikely that mts-targetting of
GLUT-4accounts for adipocyte insulin resistance, as no gross changes in
subcellular distribution of GLUT-4 were observed.
It is interesting to note that in an analysis of adipocytes from SHR rats,
Reaven et al., (1989) clearly demonstrated a decrease in GLUT-4expression
compared to normotensive animals. In addition, Haring et el., (1992) report
that GLUT-4expression in muscle from the SHRstrain is unchanged compared
to control (normotensive) strains. These results are distinct from those
observed here in the Milan hypertensive rat. However, a relative of the SHR,
the obese, hypertensive SHR/N-cp, exhibits significantly reduced skeletal
muscle GLUT-1levels [Marette et el., (1993)]. Such data add further weight to
1(x)
the polygenic nature of the syndrome of insulin resistance and
hypertension.
Given the variability of the results observed for Milan, SHR,ZDFZucker rats
etc., and the observation that GLUT-4levels are modulated by the glycaemic
status of the animal, it is not possible to draw any firm conclusions regarding
the relevance of the decrease in GLUT-4 expression in the Milan
hypertensive rat to the aetiology of hypertension. As will be discussed in
Chapter 4, one way to address this issue is to perform genetic linkage studies
of in-bred populations and to determine whether decreased GLUT-4levels co-
segregate with the hypertensive phenotype.
3.3.2 Glucose transporter expression in liver.
Glucose transport in hepatocytes is mediated via the GLUT-2isoform [Gould &
Bell. (1990); Bell et al., (1990)]. Our results show that there is no significant
change in hepatic GLUT-2expression in the hypertensive state (Fig. 3.2).
This result is perhaps unsurprising since previous studies of the insulin-
resistance associated with hypertension has indicated that the insulin
resistance is localised exclusively to the peripheral tissues. Given the high
capacity of the liver-type glucose transporter, it would in any case be
unlikely that small changes in the level of expression would exert anything
other than relatively minor effects on whole body glucose homeostasis.
Nevertheless, here we show for the first time that the expression of the
hepatocye glucose transporter is not altered in the Milan hypertensive rat
model.
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3.5.3 Glucokinase and glucose-6-phosphatase.
Glucokinase and glucose-6-phosphate are hepatic enzymes that playa key
role in the maintainance of whole body glucose homeostasis. Preliminary
reults of experiments carried out in Dundee in collaboration with Dr. Ann
Burchell would suggest that there is no decrease in the specific activity of
glucokinase, in the Milan hypertensive rat strain,. This enzyme acts as the
rate-limiting step in the utilisation of glucose and plays a crucial role in
regulating the secretion of insulin by pancreatic ~cells. In insulin resistant
states circulating blood glucose levels are elevated. A defect in glucokinase
would result in a decrease in the rate of glucose phosphorylation possibly
resulting in hyperglycaemia. These results are preliminary and further
work would be required to confirm the GKactivity as bona fide. However,
they do suggest that in the Milan strain, defective liver GKactivity does not
contribute to the hyperglycaemia.
Glucose-6-phosphatase is a main enzyme in the homeostatic regulation of
blood glucose concentration, as it catalyses the terminal step in the
gluconeogenesis pathway. The preliminary results of the Glu-6-pase assays
show that there is no difference in the Vmaxin the hypertensive rat strain.
3.5.4 Glucose transporter expression in brain regions
and changes with hypertension.
Glucose is the main energy source for mammalian brain. A previous study
from this laboratory has indicated that different brain regions exhibit
distinct levels of GLUT-1and GLUT3-transporter isoforms [Brant et al. (1993)].
Moreover, certain brain regions express the insulin-responsive glucose
transporter, GLUT-4;raising important questions regarding the function of
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this protein in these regions, and how its activity may be regulated by insulin
and the subsequent neuronal consequences of increased glucose transport
[Livingstone et al., (1994)].
The results of this analysis indicate that changes in the patterns of glucose
transporter expression are coincident with the hypertensive state, but these
changes are restricted to defined brain regions. For example, the parietal
cortex exhibits a large (-2-fold) increase in GLUT-1 expression, with a
corresponding decrease in GLUT-3expression. In contrast, the hippocampus
exhibits a decrease in GLUT-3levels independently of any change in GLUT-1
levels, and the cerebellum exhibits markedly increased GLUT-1and GLUT-3
levels, together with an increase in GLUT-4content. It has been established
that in certain brain regions, neuronal output may be modulated by glucose
levels in the cerebrospinal fluid [Marfaing-Iallat & Penicaud (1993a);
Marfaing-Jallat et al. (1993b)], thus the changes in glucose transporter levels
reported here may have a significant impact on brain function in the
hypertensive state. It will be of interest to determine whether such changes
in transporter levels are localised to specific nuclei or regions within these
affected areas.
Although the metabolic consequences of expression of GLUT-4 in the
cerebellum remain to be determined, these results are interesting in so far as
GLUT-4 expression in this region is markedly elevated. Thus, in different
tissues of the same animal group (hypertensives), GLUT-4expression is either
profoundly decreased (muscle), unaffected (adipose tissue) or increased
(cerebellum), suggesting that the GLUT-4 gene is under precise tissue-
specific control.
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3.5.5 The role of leptin and Neuropeptide Y (NPY) in
circulating glucose levels.
The brain was also examined as it plays a key role in the control of feeding
and hormonal regulation of glucose metabolism both directly and indirectly.
The first insight into the brain controlling feeding came in 1958 when
Hervey noted the presence of a hormone that regulated body weight through
an interaction with the hypothalamus. This hormone is now known as leptin,
the "fat-melting hormone". It has now been well established that leptin
resistance accounts for some cases of human obesity. This phenomenon has
been further investigated using several obese rodent strains [Caro et al.
(1996)]. As with insulin resistance, the animal models studied differ in their
phenotype. The db/db mouse and fa/fa mouse both contain mutations in the
leptin receptor, and the ob/ob mouse strain does not produce leptin [Zhang et
al. (1994)].
As discussed previously it has been proposed that most obese humans are
resistant to their exogenous production of leptin [Caro et al., (1996)].
Furthermore, it has been demonstrated that the product of the obese gene,
leptin, is capable of inducing weight loss in the ob/ob mouse. The weight loss
after leptin adminstration has been shown to due to decreased appetite and
food consumption. Also Ieptin administration actually increased
thermogenesis and activity levels. Additionally, it has been observed that
there is a normalisation of hyperglycaemia and hyperinsulinaemia prior to
any significant weight loss [Campfield et al., (1995)].
Further studies by Campfield et al., (1995) suggests that specific brain areas
are the target for leptin, including high-affinity leptin binding in the rat
hypothalamic plasma membrane. Subsequently it has been shown that
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chronic leptin adminstration decreased hypothalamic neuropeptide Y (NPY)
mRNAand directly suppressed NPYrelease from isolated perfused normal rat
hypothalamus. Hypothalamic NPY stimulates food intake, decreases
thermogenesis, and increases plasma insulin and corticosteroid levels.
Therfore , NPYappears to be a logical transducer system for leptin action.
Experiments involving leptin administration also proved the concept of
leptin resistance. A model of diet-induced obesity required 5-10 fold more
leptin to achieve the equivalent weight loss of that produced in the ob/ob
mouse. Studies have also shown that in humans, serum leptin concentrations
reflect the amount of adipose tissue in the body.
As leptin appears to be involved in the mechanism of conserving energy
during food deprivation and preventing obesity during periods of energy
excess, the relationship between insulin and leptin has been investigated.
Acute and chronic administration of insulin in vivo and in vitro increases
adipose tissue ob mRNAand therefore leptin synthesis in rodents [Saladin et
al. (1995». Although ob mRNAsymuesis increases, a rise in the secretion of
leptln only occurs in the final 24 hours of a 3-day hyperglycaemic clamp.
This delay in the insulin-stimulated secretion of leptin demonstrates that it
may be the consequence of the trophic effect of insulin on adipocytes, rather
than one of the classical metabolic responses to insulin. little is known about
the signalling pathways followed after leptln binds to the receptor. This area
is currently a black box: it may arise that leptin transport, receptor and
signalling are all normal and that the defect resides in the leptin transducer
system.
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3.5.6 Model of NPY action
Hypothalamic neuropeptide Y-ergic neurones control energy balance in part
by stimulating feeding and inhibiting thermogenesis [Stephens et al. (1995)].
Previous studies have shown that leptin decreases NPYin normal animals,
with a suppression of appetite through an unknown pathway. The increase
in thermogenesis is likely due to an increase in sympathetic out-flow that
ultimately activates the release of norepinephrine from sympathetic nerve
terminals. This in turn activates the fl3 adrenergic receptor in brown adipose
tissue. When norepinephrine binds to the adrenergic receptor in fat cells, it
raises their metabolic rate by increasing expression of the gene that encodes
uncoupling protein. This protein, present in the inner membrane of the
mitochondria, releases energy from fatty acids as heat. The relevance of
leptin's regulation of thermogenesis in humans, if any, is unknown at this
time. This is particularly true, since humans have little brown fat compared
with rodents. The above paragraph represents a theoretical model of NPY
acting as the leptin transducer system This model may be inaccurate and it
may be that such a fundamental physiological function as maintainance of
energy balance is regulated by a multi-dimensional system with overlapping
control pathways.
It is clear that specific brain regions, primarily the hypothalamus, play a
role in the controlling feeding and hormonal regulation of glucose
metabolism. Leptin and NPYsynthesised and secreted by the brain have been
shown to be involved in insulin action. Therefore when discussing insulin
resistance and hyperglycaemia it is important to remember the role played
by leptin and NPY.
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Our demonstration that glucose transporter levels are changed in defined
brain regions may have profound consequences in terms of glucose-induced
neuronal output, and also potentially in hormonal secretion (eg NPY,leptin).
Clearly, on the basis of the data presented we can draw no firm conclusions in
this regard. Nevertheless, the data suggest that such studies may offer
fruitful lines of future research.
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3.5.7 Limitations of the study
i) Due to the constraints of the laboratory's animal licence we were
unable to perform any experiments to calculate the rate of glucose transport
or the degree of insulin resistance in the Milan strain. This is unfortunate as
it would have been desirable to back up our observations with a direct
examination of glucose transport. Therefore, we can only speculate on the
effects our observations have on glucose transport and insulin resistance.
ii) As stated previously this is a study of one rat strain and there is
already information present in the literature that the degree of insulin
resistance, levels of glucose transporters and degree of hypertension varies
significantly between strains. It has been shown from many studies on this
topic that both insulin resistance and hypertension are polygenic diseases
with many variable parameters. This means that the conclusions drawn from
this study may only be relevant to the Milan rat strain.
Further to this we decided to examine the F2 progeny of the SHRSPrat strain.
This F2 population has blood pressures ranging from normotensive to
extremely hypertensive, therefore we wished to examine the levels of glucose
transporters to see how they correlate with blood pressure. This enables us to
look at glucose transporters with blood pressure being the only variable.
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3.6 Summary
Wehave shown that skeletal muscle from the Milan hypertensive rat exhibits
a decreased level of expression of the insulin-regulatable glucose transporter
GLUT-4,compared to its normotensive relative. This result is likely to account
at least in part for the insulin resistance associated with this strain. No
change in hepatic or adipocyte glucose transporter levels were observed.
Marked changes in the expression of GLUTs1, 3 and 4 were observed in
distinct regions of the hypertensive rat brain, the significance of which
remains to be elucidated.
These results suggest that a defect in the expression of GLUT-4in muscle may
account for the insulin resistance associated with the elevated blood pressure
of the hypertensive group. However, in order to further address this, we
decided to extend these studies into another animal model system, and to
examine the levels of GLUT-4expression in the Stroke Prone Spontaneously
Hypertensive Rat, and in the progeny of a cross between these animals and a
normotensive WKYcontrol strain.
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Chapter 4
GLUT Levels in Stroke-Prone Spontaneously Hypertensive
Rats: Comparison of Parental and F2 Generation Animals.
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4.1 Aims.
The aims of this chapter are as follows:
1. To examine facilitative glucose transporter levels in muscle of
SHRSPanimals compared to parental WKYstrains.
2. To analyse the expression levels of GLUT-4in skeletal muscle of
SHRSPanimals in the F2 generation of a cross of SHRSPwith WKY
animals, and to correlate GLUT-4levels with blood pressure.
3. To examine sex-dependent expression of GLUT-4in SHRSPanimals.
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4.2 Introduction.
In the previous chapter we showed that in hind-limb muscle hypertensive,
insulin resistant Milan rats had decreased intracellular GLUT-4 levels in
comparison with isogenic Milan normotensive controls [Campbell et al.
(1995)]. Wewished to determine whether this decrease was also evident in
other rat models of hypertension. As a model system, in this section we used
the stoke-prone spontaneously hypertensive rat (SHRSP).The SHRSPmodel is
considered to be one of the most realistic experimental models of human
essential hypertension [Clark et al., 1996»). As in humans, the male SHRSP
display higher blood pressure than female. This is also true of the more
commonly used spontaneously hypertensive rat (SHR). A further important
aspect of the choice of SHRSPis the demonstration that crosses between
parental SHRSPand control (WKY)animals produce off-spring with blood
pressures which span the range from normotensive to extremely
hypertensive. The F2 progeny provide an ideal model to examine the effect of
blood pressure on relative levels of facilitative glucose transporters present
in tissues, as the changes in GLUTexpression can be directly correlated with
blood pressure (measured concomitantly in the same animals). Furthermore,
the potential for subsequent genetic analysis of the gene(s) which regulate
GLUTexpression has been amply demonstrated by recent studies of such
animals [Jeffs et al. (1997)]. Any reduction in GLUTlevels, particularly in
skeletal muscle GLUT-4,may account for the insulin resistance observed in
these animals, and the results may be used as an indicator as to whether or
not blood pressure affects the levels of GLUTspresent in insulin responsive
tissues.
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4.3 Methods.
The WKYand SHRSPrats were descendants of the two strains maintained at
the University of Michigan. After arrival in Glasgow in 1991 the colonies of
SHRSPand WKYwere established by mating brother X sister. In order to
establish the SHRSP F2 population two reciprocal crosses were then
performed. In brief, 1 male SHRSPwas mated with 2 WKYfemales (cross 1)
and 1 male WKYwas mated with 2 SHRSPfemales (cross 2) to generate the F1
progeny. Subsequently the F1 rats of each cross (3 males and 6 females) were
brother X sister-mated to generate F2 rats. The pups are weaned and sexed
after 3 weeks and housed according to sibling group and sex thereafter.
Blood pressure measurements were performed over long-periods using
telemetry probes inserted into the animals. These probes send radio signals to
detector units which record the diurnal variations in blood pressure in
individual animals. Other parameters measured included age, sex, weight, and
left ventricular volume. Blood pressure measurements were correlated by Dr
Delytb Graham and Professor Anna F. Dominiczak (University Department of
Medicine and Therapeutics, Western Infirmary, Glasgow) who generously
made this data available to us. Statistical analysis was performed using ANOVA
by the University of Glasgow Department of BiologicalStatistics.
GLUT-4levels in both LDMand PM fractions of hind-limb skeletal muscle
were measured using the sub-cellular fractionation and immunoblotting
protocols outlined in chapter 2. In these experiments, GLUT-4 levels in
LDM/PM fractions from individual rats were determined by quantitative
immunoblotting. On each immunoblot, duplicate lanes of GLUT-4standard
were loaded, and GLUT-4levels in fractions isolated from individual animals
were compared to this standard. In the analysis of all the samples in this
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chapter, this GLUT-4standard was constant. Prior to analysis of GLUT-4levels
in these fractions, we showed that the immunoblot signal obtained for these
standards was well within the linear response range of the
antibody/detection system. Care was taken to ensure all 'experimental'
samples were measured within the linear range for each antibody. All
fractions were assayed at least three times and the values presented are mean
± s.d. for the three independent blots.
120
4.4 Results.
4.4.1 Analysis of blood pressure in SHRSP AND SHRSP F2
The first criteria to be analysed is the blood pressure measurements from all
the strains examined in this chapter. Figure 4.1 illustrates that the SHRSPrat
strain has by far the highest mean systolic blood pressure of 222.3 mmHg ±
26.7,asmeasured by telemetry probes inserted into the animals, compared to
156.8mmHg± 10.6mrnHgfor the control group. Additionally treatment with
losartan, which is a blocker of the AT1 receptor for angiotensin II,
significantly lowers blood pressure to normotensive levels. Interestingly,
the SHRSPF2 strain had an average cystolic blood pressure of 167.75 mmHg ±
22.75 mmHg, which is only slightly hypertensive. This is not altogether
surprising as the SHRSPF2 generation is comprised of individual animals
which display blood pressure levels from normotensive to extreme
hypertensive.
As stated in the introduction of this chapter, the SHRSPrat strain is regarded
as the hypertension model closest related to human essential hypertension,
in particular that the severity of hypertension is gender associated. This is
demonstrated in figure 4.2 which illustrate that the mean male blood pressure
is Significantly higher than that of its female counterpart. The males
recorded an average blood pressure of 239.1 mmHg ± 16.9 mmHg, compare to
the females 194.2 nunHg ± 5.2 nunHg. Furthermore, both the male and female
SHRSPhave blood pressures much greater than the normotensive WKY
control. Additionally figure 4.3 highlights that male SHRSPrats have a
greater average body weight than the female counterpart. The blood
pressures from both sexes are much greater than that of the control
normotensive WKYstrain.
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Figure 4.1
Differences in blood pressure between SHRSP, SHRSP F2 and WKY
rat strains.
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Figure 4.1
Differences in blood pressure between SHRSP, SHRSP F2 and WKY
rat strains.
A graphical illustration of the differences in the blood pressure of SHRSP,
SHRSPF2 and WKYrat strains. The blood pressure was measured by telemetry
probes over a period of approximately 7 days.
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Figure 4.2
Analysis of the relationship between blood pressure and gender
in the SHRSP and WKY rat strains.
A graphical illustration of the relationship between blood pressure and
gender in the SHRSPgeneration, compared to the blood pressure measured in
the normotensive WKYstrain.
Figure 4.2
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Figure 4.3
Comparison of male and female mean body weights from the
SHRSP, SHRSP F2 and WKY rats.
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Comparison of male and female mean body weights from the
SHRSP, SHRSP F2 and WKY rats.
The graph illustrates the mean body weights, in grammes (g), of the animals
measured immediately prior to sacrifice.
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The SHRSPF2 strain displays average blood pressure that does appear to be
linked to gender. As stated earlier the average blood pressure for the total
group was 167.75 mrnHg ± 22.75 mmHg. Looking at the blood pressures for
males and females separately, as is shown graphically in figure 4.4, it is
apparent that the males have a higher mean blood pressure. For males the
average blood pressure being 172.5 mmHg ± 8.6 mmHg, and the average for
females being 164.7 mmHg ± 11.3 mmHg.
Male rats were found to have higher average body weights than their female
counterparts (figure 4.3); this lends further support to the argument that this
rat strain is a realistic experimental model of essential hypertension, as these
sex-dependent differences in blood pressure are similar to those reported in
human clinical cohorts.
Figures 4.4 and 4.5 illustrates the range of blood pressures displayed by the
SHRSPF2 generation, separated by gender. The mean values are presented in
figure 4.4, and the range of values for males and females shown in figure 4.5.
4.4.2 GLUT-4 levels in the SHRSP and SHRSP F2 skeletal muscle
After measuring the relative amounts of intracellular GLUT-4 from the
skeletal muscle from individual animals (both WKYcontrols, parental SHRSP
and F2animals), I examined the possibility of GLUT-4levels correlating with
gender or blood pressure in these animals. Representative immunoblots of
GLUT-4 in such animals are presented in figure 4.6.
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Figure 4.4
Mean blood pressure measurements in the SHRSP F2 generation.
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Figure 4.4
Mean blood pressure measurements in the SHRSP F2 generation.
Bloodpressure measurements were made in individual rats over 5 days using
radio telemetry probes. Shown are the mean BP values for the SHRSPF2
population, both as a total group, and separated be gender (MalesM; Females
F).The mean values for males and females are not statistically different.
Figure 4.5
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in the SHRSP F2 progeny.
Analysis of the relationship between blood pressure and gender
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Figure 4.5
Analysis of the relationship between blood pressure and gender
in the SHRSP F2 progeny.
A graphical illustration of the relationship between blood pressure, as
measured by telemetry probes, and gender in the SHRSPF2 generation. The
graph has been plotted in two columns, one male and the other female. Each
point marks the average blood pressure for an individual animal.
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Figure 4.6
Immunological analysis of intracellular GLUT-4 levels in SHRSP
F2 skeletal muscle.
A representative immunoblot of the intracellular GLUT-4 levels present in
the skeletal muscle of SHRSP F2 animals is shown. Low density microsomal
membrane protein (25I-lg) from each individual was electrophoresed on 10%
SDS-PAGE,prior to transfer onto nitrocellulose membranes. Immunoblots
were developed with anti-GLUT-4 antibodies (Campbell er al. 1995). Shown is a
representative blot from F2 animals of the SHRSPstudy group. The bands on
the developed autoradiograph were cut out of the nitrocellulose and the 125-1
labelled antibody was y counted. AGLUT-4 standard was run on the SOS-PAGE
in order to allow a comparison between each immunoblot. Blots were repeated
at least twice for each muscle fraction, and the mean value calculated as a
percentage of the signal obtained from the control GLUT-4 standard. These
values were used to calculate the data for figure 4.7.
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Figure 4.7
Immunological analysis of skeletal muscle intracellular
membrane GLUT-4 content in SHRSP, SHRSP F2 and WKY strains.
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Figure 4.7
Immunological analysis of skeletal muscle intracellular
membrane GLUT-4 content in SHRSP, SHRSP F2 and WKY strains.
Intracellular GLUT-4levels were determined in triplicate for animals in each
of the study groups (WKY,SHRSP parentals, SHRSP F2 etc.) as outlined in
figure 4.6. These mean GLUT-4value for each group was then calculated, and
Shownabove is this value ± s.d. for each group. There was no statistical
difference between any of these groups.
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Surprisingly, we observed no statistical difference in GLUT-4levels in either
PM (not shown) or LDM fractions (fig 4.7) from SHRSPparental animals
compared to control (WKYstrains).
Despite male rats having higher blood pressure and greater body weight (see
figure 4.3 above), no significant difference was observed in the amount of
GLUT-4present in each of the fractions, regardless of sex (figure 4.8).
However, as can be seen in figure 4.9 blood pressure increases with
increasing body weight. This observation is also noted in human
hypertension. Furthermore this trend is noticeable in both male and females
alike (figure 4.10). Nevertheless, GLUT-4levels did not appear to correlate
with either of these parameters.
Wealso examined the relationship of GLUT-4and blood pressure in the total
cohort (figure 4.11) and separated on the basis of gender (figure 4.12). From
this data it is apparent that there is no correlation between blood pressure
and the level of GLUT-4detected in the low density microsomes (LDMs)of the
hind-limb skeletal muscle. This finding highlights the diverse nature of
insulin resistance and would appear to emphasise the differences between
rodent models of hypertension and insulin resistance.
Another topic under investigation in the course of this chapter is the effect
of gender upon skeletal muscle GLUT-4,body weight and hypertension. For
the SHRSPF2 strain our findings reveal that there is no difference in GLUT-4
levels between male and female individual rats. Not surprising the males have
a slightly higher mean blood pressure, but there is no significant difference
in average body weight nor relative levels of the glucose transporter, GLUT-4.
Asstated in the previous
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Figure 4.8
Analysis of the relationship between gender and skeletal muscle
intracellular GLUT-4 SHRSP, SHRSP F2 and WKY strains.
This shows figure 4.7 separated into male and female average intracellular
GLUT-4levels (see figure 4.5 for explanation). Data calculated after running
25ltg protein on SDS-PAGE,western blotted and the resultant band from the
autoradiograph cut out of the nitrocellulose and y-counted.
Figure 4.8
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Figure 4.9
Analysis of the relationship between blood pressure and body
weight in the SHRSP F2 progeny
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Figure 4.9
Analysis of the relationship between blood pressure and body
weight in the SHRSP F2 progeny
This graph depicts the relationship between body weight (measured in
grammes) and blood pressure. Each point in the graph represents one
individual rat of the SHRSPF2 generation.
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Figure 4.10
Gender and the relationship between blood pressure and body
weight in the SHRSP F2 progeny
The SHRSPanimals from the F2 generation (figure 4.9) were considered
separated by gender. The results of this analysis are shown above. In both
cases, there is a positive correlation between blood pressure and body weight,
as has been reported by others (see text for details). Note that for clarity, not
all points have been presented.
Figure 4.10
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Figure 4.11
Analysis of the
intracellular GLUT-4
generation
relationship
and blood
between
pressure
skeletal muscle
in the SHRSP F2
A graphical illustration of the relationship between blood pressure, as
measured by radio probe telemetry, and intracellular GLUT-4levels.
determined by quantitative immunoblotting, in the SHRSPF2 generation.
Each point in the graph represents an individual animal. There is no
relationship evident between these variables. Note that for clarity, not all
points have been presented.
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Figure 4.11
Analysis of the relationship between skeletal muscle
intracellular GLUT-4 and blood pressure in the SHRSP F2
generation
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Figure 4.12
Gender and the relationship between intracellular GLUT-4 and
blood pressure in the SHRSP F2.
This separates figure 4.11 into male and female individuals. However it still
demonstrates a lack of correlation between GLUT-4levels and blood pressure.
Figure 4.12
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Figure 4.13
Analysis of the relationship between body weight and skeletal
muscle intracellular GLUT-4.
This illustration separates the SHRSPF2 generation into males and females
and examines the relationship between body weight and GLUT-4. Linear
correlation coefficients of these graphs do not reach statistical significance.
Note that for clarity, not all points have been presented.
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Figure 4.13
Male body weight Vs. LDM GLUT-4 levels
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chapter, many insulin resistant rodent models do not express reduced levels
of GLUT-4. Additionally there is no relationship between body weight and the
level of GLUT-4(Fig 4.13). Previous work had shown that there is a reduction
in GLUT-4correlating with increasing obesity. However, many hypertensive
rat models are obese and have normal GLUT-4 expression.
This study demonstrates that the decrease in muscle GLUT-4levels observed in
a related animal model of hypertension, the Milan rat, is not observed in this
model of hypertension. Since the progeny of the SHRSPx WKYcross exhibit
blood pressures which span the range from normotensive to hypertensive,
then if a decrease in skeletal muscle GLUT-4 was tightly linked to the
hypertensive state, this link should be manifest among this progeny. Our
results clearly indicate that this is not the case. We conclude that decreased
GLUT-4 in skeletal muscle is not tightly correlated with the hypertensive
state in this model of hypertension.
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4.5 Discussion.
In order to compare the relationship between blood pressure and GLUT-4
levels in the SHRSPF2 generation, we must initially consider the levels of
GLUT-4found in the parental SHRSPanimal. WKYanimals were chosen as
control subjects as they are the closest related normotensive strain. However,
it is important to note that the WKY,unlike the Milan normotensive strain, is
not an isogenic control. When comparing skeletal muscle GLUT-4 levels
between WKYand parental SHRSPanimals, it is apparent that there are no
differences in GLUT-4 levels between strains, either in the low density
microsomes or the plasma membrane.
As was discussed in the previous chapter many rodent models of insulin
resistance have been examined in recent years with many different defects
in GLUT-4levels and the insulin signalling mechanism being identified.
These models have shown that no one defect is consistently displayed and
therefore being pin-pointed as the causative "agent" in insulin resistance.
Thus, it is perhaps not surprising that the SHRSP parental strain is not
defective with regard to GLUT-4levels. When looking at gender, although the
male rats have significantly higher mean blood pressure, there was no
difference in GLUT-4levels in any sub-cellular fraction considered.
When looking at the SHRSPF2 generation the story is somewhat similar. As
previously stated SHRSPF2 individuals display blood pressures ranging from
normotensive to extremely hypertensive but there is no correlation between
blood pressure and GLUT-4levels in these animals, either as a total group or
separated on the basis of gender. This result is further proof that rodent
models with insulin resistance are not necessarily defective in GLUT-4.
Furthermore, it confirms and extends our observations that there is no
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relationship between GLUT-4level and blood pressure in the hypertensive
parentals (compared to the WKYcontrol strain). Additionally, the SHRSPF2
GLUT-4levels are not gender dependent, even though the males have a
slightly higher average blood pressure, the relative levels of GLUT-4are
unchanged between males and females. We were unable to demonstrate a
correlation between GLUT-4levels and blood pressure values for the parental
SHRSPanimals compared to WKYcontrols. Hence , it is not possible to
statiStically analyse the data from the SHRSPF2 generation using ANOVAto
definitively delineate the relationship of blood pressure to GLUT4levels in
these animals. However, inspection of the data would appear to not reveal any
correlation between these variables .
.Although the lack of a correlation between blood pressure and GLUT-4
Contradicts the data obtained from the Milan rat strain in chapter 3, it must
be remembered that insulin resistance, hypertension and hyperglycaemia,
although related, are independent disease states with multiple genes involved.
Furthermore, as discussed in chapters 1 and 3 of this thesis there are many
means of becoming insulin resistant besides a defect in GLUT-4expression.
Other avenues have to be explored for this particular rat model including
inefficient targetting of GLUT-4 to the plasma membrane, defects in the
insulin receptor signalling mechanism, and also the possibility of failings at
the level of the insulin receptor itself. Altered expression of one or many of
the genes involved in insulin -stimulated sugar transport and blood pressure
Controlmay produce the resultant phenotype.
With regard to insulin resistance, and GLUT-4in particular, many different
rOdentmodels and human subjects have been studied. From these studies no
clear pattern has been observed with GLUT-4 levels being increased,
decreased or even unchanged depending upon which model and interestingly
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which tissue was under examination. In a study of human patients with
either obesity or NIDDMit was observed that altered levels of GLUTs1 and 4
were not responsible for insulin resistance [Pedersen et al. (1990)]. However,
the streptozotocin diabetic, insulin deficient rat GLUT-4mRNAand protein
are reduced in both skeletal muscle and adipose tissue. Furthermore the
decrease is associated with insulin deficiency, as after insulin treatment ,
both the mRNAand protein content are normalised in fat tissue [Garvey et al.
(1989); Kahn et al. (1989)]. Consequently, it is not possible to offer a single
unifying mechanism for insulin resistance associated with all clinical
conditions. Hence, our observation here that defective GLUT-4expression is
not associated with blood pressure suggest that at least for SHRSPs,defective
GLUT-4expression is not a contributing factor to insulin resistance.
In recent years the levels of GLUT-4in diabetic patients has been examined
closely, and in particular the effect exercise has on the amount of glucose
transporter protein present. In 1993 Koivisto et al. reported that exercise
reduces the muscle glucose transport protein (GLUT-4)mRNA Hi type 1
diabetic patients. However, in patients with NIDDM, physical training
increases muscle GLUT-4protein and mRNA[Dela et al. (1994)]. In young,
healthy subjects, physical training increases insulin-stimulated glucose
transport in skeletal muscle. Similar studies of training increasing whole-
body insulin action and GLUT-4protein content in aged people with impaired
glucose tolerance have been published [Hughes et al. (1993)]. As previously
mentioned the study of Dela et al. (1994) observed an increase in the level of
GLUT-4mRNAin the NIDDMpatients. However,the level of GLUT-4mRNAwas
lower in the NIDDMpatient than in the control subjects, irrespective of
training status. Other investigators have found that GLUT-4mRNAin skeletal
muscle is unchanged [Garvey et al. (1992); Pedersen et al. (1990)] or even
higher [Eriksson et al. (1992)] in NIDDMthan in age- and weight-matched
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control subjects. Thus, data on GLUT-4mRNAcontent in NIDDMpatients is
controver sial.
There are further conflicts when looking at GLUT-4protein levels in rodent
models of diabetes. This probably reflects a combination of the use of
different animal models with varying degrees of insulin resistance. A
further problem in examining GLUT-4 levels in skeletal muscle is the
difficulty in preparing sub-cellular fractions from this tissue. Taking all this
into consideration the consensus view is that muscle GLUT-4levels are
unchanged, with some notable discrepancies. Male rats from the ZDFI art-ie
Zucker rat strain are obese and insulin-resistant, but go on to develop overt
diabetes. In this strain GLUT-4 levels are reduced by 40% in both skeletal
muscle and adipose tissue, accounting for insulin resistance. This reduction
in GLUT-4is restored by combating the hyperglycaemia, suggesting that this
may be contributing to impaired expression of the transporter. Reduced
GLUT-4expression in this animal model appears to be decisive in causing
diabetes, since in other respects these animals are similar to their respective
non-diabetic strains [Friedman et al. (1991)].
Wehad hoped that analysis of the SHRSPanimal for studies of GLUT4and the
link to hypertension may offer new insight into GLUT4regulation. F2 animals
such as those outlined above offer a powerful genetically malleable tool with
which to address the segregation of genetic material with the hypertensive
phenotype. We had hoped to utilise this to address the issue of the control of
GLUT4regulation in hypertension. Unfortunately, this analysis is impossible
as the expected phenotype of reduced GLUT4expression in the hypertensive
state was not observed.
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4.6 Summary
This chapter highlights the diverse nature of insulin resistance. From the
data presented it is clear that we could not detect any reduction the
facilitative glucose transporter, GLUT-4,in the SHRSPF2 generation. These
results are consistent with many previous studies that have shown that GLUT-
4 expression and activity is not reduced in insulin resistance. Further
analysis of the insulin signalling pathway may elucidate the mechanism of
insulin resisitance associated with hypertension in the SHRSProdent model.
Chapter 5
The effect of oestrogen and derivatives upon insulin-
stimulated glucose transport in 3T3-Ll adipocytes.
149
150
5.1 Aims.
The aims of this chapter are:
1. To examine the effect of the steroids oestrogen, oestriol and
oestradiol upon insulin-stimulated glucose transport.
2. To compare these effects with those induced by dexamethasone.
3. To determine the nature of any defect in insulin-stimulated glucose
transport, including analysing the levels of GLUT-4and PI-3 kinase.
151
5.2 Introduction
5.2.1 Sex hormone effects on insulin-stimulated glucose
transport
Cardiovascular disease in postmenopausal women is a major public health
concern. A third of all women between the ages of SOand 75 are affected, and
one sixth ultimately die from the disease [Ettinger, B. (1990)]]. The use of
oestrogen replacement therapy in postmenopausal women has been shown to
reduce the risk of cardiovascular disease by about 50% compared to women
who remain untreated. However, as a result of concerns regarding
endometrial carcinoma and hyperplasia, a progestin is often used in
combination with an oestrogen to protect the endometrium from the
excessive stimulation which may occur as a consequence of unopposed
oestrogen. Notelovitz(1982) and Diamondet al., (1995) both note that the use
of progestin has been reported to counteract some of the beneficial
cardiovascular effects of the oestrogen, such as increased high-density
lipoprotein cholesterol concentrations, improved vascular tone, and glucose
metabolism.
Caefalu et al., (1994) demonstrated using the surgically postmenopausal
cynomolgus monkey that progestins alone, or in combination with oestrogens
can induce insulin resistance. Surgically postmenopausal monkeys were fed
a diet containing conjugated equine oestrogen or medroxyprogesterone
acetate, tamoxifen, or a combination of those for a period of 12weeks. Insulin
sensitivity and circulating levels of glucose were determined by frequent
intravenous-sampling and performing tolerance tests. The results of the
study suggest that progestins alone, or in combination with oestrogens, can
induce insulin resistance in postmenopausal monkeys.
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A similar induction of insulin resistance is observed in women on HRT,
although is should be pointed out that there is some ambiguity in the data
regarding glucose tolerance tests in some of these studies which has perhaps
underestimated the prevalence of this problem [Spellacy (1982)]. These
discoveries have been further complemented with research into the effect of
the oral contraceptive pill on carbohydrate metabolism. Patterns of insulin
resistance have been observed in women on the oral contraceptive pill
[Godsland et al., (1992)], and the co-existence of insulin resistance and
hyperandrogenism has been described frequently, most notably in women
with polycystic ovarian syndrome [Dunaif et al., (1992)]. Godsland et al.,
(1992) examined insulin sensitivity in women on the oral contraceptive pill.
The study looked at the effects of varying the levels of progestin while
maintaining the oestrogen component. The progestin only formulation had
no effect upon insulin sensitivity, but the combination of oestrogen and
progestin induced insulin resistance. These results suggest that it is more
likely that the oestrogen component of oral contraceptives induces insulin
resistance. The progestin component is thought to modify the effects of
oestrogen-induced insulin resistance, perhaps as a consequence of progestin
prolonging the half-life of insulin action. This means that users of the
combined oral contraceptive have elevated plasma insulin concentrations.
Therefore this has the effect of enabling the insulin resistant subjects to
sustain their rate of glucose disposal.
Dunaif et al., (1992) examined insulin resistance in polycystic ovary
syndrome (PCDS),a disease state characterised by hyperandrogenism,
disordered gonadotropin secretion, and oligo- or anovulation. Women with
PCDS display significant insulin resistance and hyperinsulinaemia. As
previously stated insulin-stimulated glucose uptake is largely mediated by
GLUT-4,hence a study was performed to determine if the reduced insulin
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sensitivity might be attributable to diminished cellular GLUT-4content. In
adipose tissue from peos patients GLUT-4content is reduced by 35%, a
reduction which probably accounts for the reduced insulin responsiveness
witnessed in this tissue.
These and other studies have provided a clear demonstration that insulin and
sex hormones interact, but the mechanistic basis of this interaction is
unclear.
5.2.2 Interactions of insulin and sex-hormones
There is a difference of opinion on the cause and effect relationship between
insulin and the sex hormones. One hypothesis which has gained the most
considerable support is that high insulin levels found in insulin-resistant
states may stimulate the ovary to induce overproduction of the sex hormones.
[Poretsky, L. (1991)]. However, what is not readily accounted for by this
theory is why insulin should promote the excess production of androgens
only, as other sex hormones are not affected by insulin.
In contrast, it has been suggested that androgens may induce insulin
resistance by an as yet uncharacterised mechanism. This hypothesis has been
based on several observations. Firstly, it has been demonstrated in some
hyperandrogenic, insulin resistant women that improvement of insulin
sensitivity is observed upon correction of the hyperandrogenism [Shoupe &
Lobo(1984)]. Secondly, Landon J., et aJ. (1963) reported the induction of
insulin resistance in normal subjects following administration of the
androgen methandienone. They reported a decrease in glucose clearance
from healthy men after 2 -4 weeks of methandienone ingestion.
Interestingly, they reported normal insulin sensitivity, which was measured
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by the decrease in serum glucose concentration after insulin administration.
Additionally, the same group noted an increase in plasma insulin response to
tolbutamide administration, which is indicative of impaired insulin
sensitivity, post methandienone treatment. Further studies by Cohen &
Hickman (1987) demonstrated a causal link between anabolic steroid abuse
and insulin resistance in young athletes. Specifically they looked at the
effect of ingesting anabolic steroids on insulin sensitivity in powerlifters.
The subjects abusing the steroids ingested large doses of approximately 200
mg/day for a period of up to seven years. These athletes had diminished
glucose tolerance when compared to a non-steroid using group, whilst
having substantially higher post-glucose serum insulin concentrations. The
diminished glucose tolerance is likely to be secondary to the insulin
resistance. The reduction in glucose tolerance could be explained in two
.ways. Firstly, there is the possibility that inadequate insulin is released in
response to an increase in plasma glucose concentration, as is the case with
type 1 diabetes mellitus. Another possibility is that there is a specific tissue
resistance to insulin action, this situation is associated with insulin resistance
in subjects suffering from obesity. The insulin resistant powerlifters
displayed both elevated fasting insulin concentrations and very high post-
glucose insulin concentrations indicating that the diminished glucose
tolerance was the result of tissue-specific insulin resistance.
Further key evidence in favour of such a link has come from studies of male
to female and female to male transsexuals [Polerdman et al., (1994)J. The
subjects were monitored before, during, and after 4 months of hormone
administration. The females were treated with injections of testosterone
ethers (250 mg/day); males participants were administered with ethinyl
oestradiol (0.1 mg/day) alone, or a combination of ethinyl oestradiol and
cyproterone acetate. Throughout the study blood glucose and plasma insulin
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levels were monitored using hyperinsulinemic-euglycemic clamping. This
study reached the conclusion that sex hormone administration, Le.
testosterone treatment in females and ethinyl oestradiol in males, can induce
insulin resistance in healthy subjects.
Interestingly, a recent study using sensitive clamp techniques has shown
that normal puberty is associated with a reduction in insulin stimulated
glucose uptake in peripheral tissues [Cutfieldet al. (1990)];although growth
hormone levels may in part modulate this response, elevated levels of
androgens and oestrogens may also contribute. High levels of progesterone
and oestrogens in normal pregnancy are also associated with decreased
insulin sensitivity, this also provides some support, albeit anecdotal, to
suggest that androgens and oestrogens may be involved in the aetiology of
insulin resistance.
5.2.3 Insulin resistance: molecular pathology
The inability of peripheral tissues to respond to insulin i.e. insulin resistance,
has been identified in a number of clinical conditions, many of which are
associatedwith an increase in blood pressure [reviewed in Uvingstone et al.
(1995». These include ageing, obesity and non-insulin dependent diabetes
mellitus (Type II diabetes). For example, it has recently been demonstrated
that adipocytes from lean, non-diabetic essential hypertensives exhibit
insulin resistance correlated with an inability of insulin to stimulate glucose
transport into these cells. Insulin resistance has also been reported in several
model systems for hypertension [seeabove and reviewed in Uvingstone et al.
(1995)].
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Such studies have identified potential points of lesion in the action of insulin
to stimulate glucose disposal, and have been discussed in detail in previous
sections of this thesis. These type of studies have not, however,been extended
into studies of sex-hormones and insulin resistance, but offer a suitable
framework within which to explore the molecular pathophysiology of other
insulin resistant states.
5.2.4 Insulin resistance and sex hormone-binding protein
As noted above, sex hormones may be involved in the determination of risk
factors for non insulin-dependent diabetes mellitus (NIDDM). In vivo
assessment of sex hormones and binding proteins in both premenopausal and
post menopausal women has suggested that decreased sex hormone-binding
globulin (SHBG)is associated with higher circulating levels of glucose and
insulin concentrations [Haffner, S.M (1996)]. Further studies have shown
that increased insulin resistance has been associated with decreased SHBG
levels. SHBGis thought to oe an indirect measure of androgenecity with its
concentrations mainly determined by the level of free oestrogens and
androgens [Anderson, D.G. (1974)]. Increased glucose and insulin
concentrations were associated with increased testosterone and decreased
SHBGin non-diabetic subjects in the San Antonio Heart Study. Obesity is also
another factor linking insulin resistance and SHBG.Upper body adiposity has
also been associated with increased free testosterone and decreased SHBG.
While overall adiposity is associated with increased pancreatic insulin
secretion, increased upper body adtpostty is associated with decreased hepatic
clearance of insulin. In addition, hepatic clearance of insulin shows a
positive correlation with concentrations of SHBG. Women with polycystic
ovary syndrome (PCOS)who have increased levels of free testosterone, have
increased insulin and glucose concentrations. Finally, although few studies
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have been done on the whether the alteration of androgen levels predict
metabolic disease, two studies have shown that low levels of SHBGpredict the
incidence of NIDDM in women [Haffner et al., (1993);Lindstedtet al., (1991)] .
5.2.5 The known effects of steroids on adipose cells and glucose
transport
Even before the isolation and characterisation of GLUT-4Garvey et al., (1989)
noted that the glucocorticoid, dexamethasone regulates the glucose transport
system in primary cultured adipocytes. They discovered these cells became
insulin resistant following exposure to the steroid. Furthermore the
mechanism of insulin resistance differed depending on the length of time the
cells were exposed to dexamethasone. Short term treatment of between 90-120
minutes resulted in rapidly decrease glucose transport in both basal and
maximally insulin-stimulated cells. This decrease was associated with a
reduction in the number of glucose transporters present at the plasma
membrane, evaluated using a cytochalasm B binding assay. This contrasts
with an increase in the amount of glucose transporters present in the LDMs
from both basal and insulin-stimulated cells. Dexamethasone treatment led to
a 22% increase in intracellular glucose transporters. These observations
indicate that dexamethasone acutely decreases insulin responsiveness by
impairing the translocation efficiency of the intracellular glucose
transporters to the cell surface.
Chronic glucocorticoid treatment led to more profound decrements in both
basal and insulin-stimulated glucose transport rates. The relative decrease in
stimulated transport was more marked at sub-maximal insulin concentrations.
Asdexamethasone did not impair insulin binding its receptor it was concluded
that the reduction in response to insulin were distal to the interaction
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between insulin and receptor. Furthermore, glucose transporter levels were
reduced at both the plasma membrane and intracellular pool. This discovery
led to the conclusion that chronic treatment with dexamethasone enhances
insulin resistance by inducing a defect in the total number of cellular
glucose transporters.
Further to these studies Saad et al., (1994) examined the effect of
dexamethasone on the regulation of the insulin receptor, insulin receptor
substrate-l (IRS-I) and phosphatidylinositol 3-kinase (PI 3-kinase) in 3T3-
F422Aadipocytes. Section 1.3 gives a detailed account of the involvement of
IRS-1 and PI 3-kinase in the insulin receptor signalling pathway.
Differentiation of these cells results in a 13-fold increase in the amount of the
insulin receptor present, a 9-fold increase in IRS-!. Additionally there was a
3.5-fold increase in PI 3-kinase protein (85kDa sub-unit) and a 16.S-fold
increase in IRS-I-associated PI 3-kinase activity.
24 hour treatment of the adipocytes with 1nM dexamethasone induced an
increase in the level of insulin receptor in these cells. Analysis of the
autophosphorylation of the insulin receptor revealed that there was a
decrease of 31%. Simultaneously, IRS-1protein levels are decreased by 56%
resulting in a decrease in IRS-l phosphorylation of 31%. The down
regulation of IRS-1was also observed in 3T3-Ll adipocytes after treatment
with dexamethasone [TurnbowM.A.et al., (1994)]. Converselydexamethasone
increased the level of PI 3-kinase by 6996,as determined by western blotting.
The combination of reduced IRS-Ilevels and increased PI 3-kinase resulted in
a 15%decrease in the association/activation between IRS-l and PI 3-kinase.
A 24 hour treatment of these adipocytes with 100 nM insulin resulted in a
decrease in insulin receptor, IRS-l and PI 3-kinase levels. Thus three of the
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early steps of insulin action may have an important role in hormone-induced
insulin resistance.
Another putative insulin receptor signal protein, pp160 has also shown to be
regulated by dexamethasone [Riceet al., (1992)]. This 160kDacytosolicprotein
is phosphorylated on tyrosine residues in response to insulin and was
postulated to be involved in signalling from the insulin receptor. It is now
established that this protein is the murine homologue of IRS-I. Chronic
exposure of fully differentiated adipocytes to dexamethasone and/or insulin
resulted in a 70-85% decrease in the expression of pp160. These results
demonstrate that pp160 is expressed in 3T3-Ll adipocytes when insulin
receptors are expressed in large numbers. Furthermore maintenance of
pp160 concentrations can be regulated by insulin and dexamethasone. The
decreased expression of pp160 caused by these factors may be related to post
receptor insulin resistance. This compliments the data from Turnbow et al.
outlined above.
Here we set out to examine the effect of sex steroids on insulin action in
isolated adipose cells. This represents a useful model to directly examine the
effects of steroids on fat cells. Furthermore, such a system may offer a
powerful model with which to probe the molecular basis of insulin resistance.
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5.3 Methods
3T3-Ll fibroblasts were grown in 10% (v/v) NCS/DMEMuntil 48 hours post
confluence. The cells were then induced to differentiate by a method detailed
in section 2.3.4.
The adipocytes were maintained for a further 8-10 days in 10% (v/v)
FCS/DMEM. 48 hours prior to assay the cells were fed with 10% (v/v)
FCS/DMEM containing one of the oestrogen derivatives at a final
concentration of between 0 and 100 nM.
Finally the cells were assayed to determine the rate of ir.sulin-stimulated 3[H]
2-deoxy-D-glucose uptake using the procedure detailed in section 2.3.8.
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5.4 Results
As stated previously in this thesis, insulin-responsive tissues, skeletal muscle
and fat, exhibit rapid translocation of GLUT-4 from the intracellular
membranes to the plasma membrane in response to insulin. This results in a
rapid increase in glucose transport, and eventually an increase in glucose
metabolism. This phenomenon can also be observed in the cultured clonal
adipocyte cell line, 3T3-Ll adipocytes. Figure 5.1 shows that in response to an
insulin stimulus, [3H] 2-deoxy-O-glucose transport into these cells is
increased between 10- to IS-fold. Figure 5.2 shows an immunoblot of sub-
cellular fractions of 3T3-Ll adipocytes treated with or without insulin. Upon
insulin stimulation there is a noticeable decrease in GLUT-4in the low density
microsomes. Furthermore, there is a corresponding increase in GLOT-4 at the
plasma membrane. This re-distribution in GLUT-4to the cell surface is
sufficient to explain the subsequent increase in glucose transport. Additional
studies have shown that there is a slight increase in GLUT-l at the cell
surface after stimulation by insulin, but this increase is not as dramatic as
that for GLUT-4(typically 3-fold for GLUT-lcompared to 12- to ls-fold for
GLUT4;see REF). As shown in Figure 5.1, the increase in [3H] 2-deoxy-O-
glucose uptake is dependent on the concentration of insulin added. The ECso
for insulin-stimulated glucose uptake is between 0.5 and 3 nM.
As stated previously insulin resistance is associated with a decrease in
insulin's ability to simulated glucose uptake via translocation of GLUT-4.
Therefore it was decided to employ the uptake of [3H] 2-deoxy-O-glucoseafter
stimulation by insulin as an index of insulin responsiveness. In the
experiments described in this chapter, we set out to examine the effects of
sex-steroids on insulin responsiveness. Ultimately, we hoped to develop a
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Figure 5.1
Dose-dependent insulin stimulated 2-deoxy-D-glucose uptake in
3T3-Ll adipocytes.
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Figure 5.1
Insulin-stimulated 2-deoxy-D-glucose uptake in untreated 3T3-L1
adipocytes.
Insulin-stimulated 2-deoxy-D-glucose uptake in 3T3-Ll adipocytes was assayed
as described in section 2.3.7 of this thesis. Insulin was added at the indicated
concentration for 30 minutes prior to measurement of deoxyglucose
transport. The data shown is from a representative experiment and was
repeated four times with similar results.
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Figure 5.2
Translocation of GLUT-4 to the plasma membrane from the low
density microsomes following insulin stimulation.
This representative immunoblot depicts the level of GLUT-4 in the plasma
membrane (PM) and low density microsomes (LDM) fractions of 3T3-L1
adipocytes, +/- insulin stimulation (lmM for 30 minutes). 2SJ.tgof protein for
each fraction were separated by 10% SDS-PAGEand inmmunoblotted using
anti-GLUT-4 antobdies as in accordance with section 2.6.
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cell system with which to examine aspects of the mechanistic basis of insulin
resistance.
Initial work performed by Garvey and co-workers demonstrated that exposure
of primary cultured adipocytes to the glucocorticoid dexamethasone induced
an inhibition of insulin-stimulated glucose transport [Garvey et al., (1989)].
These studies concluded that 20 nM dexamethasone induced a progressive
insulin resistance by acting at various stages of the insulin-stimulated
glucose transport mechanism. Acute exposure (up to 2 hours) to
dexamethasone impairs the ability of insulin to translocate intracellular
GLUT-4to the cell surface, resulting in a 35% decrease in maximal insulin-
stimulated glucose transport. After 24 hours the dexamethasone-induced
insulin resistance was shown to be the result of a 43% reduction in the total
cellular GLUT-4transporter level. In this instance the maximal insulin-
stimulated glucose transport is reduced by 55%.
These workers also assessed whether the dexamethasone-induced insulin
resistance is glucose dependent. The adipocytes were cultured in the
presence and absence of dexamethasone or insulin in the presence of up to 20
mM D-glucose. Dexamethasone treatment produced a decrease in both basal
and maximal insulin-stimulated transport (see above). In contrast, chronic
insulin treatment was unable to decrease glucose transport activity in the
absence of glucose, but led to a progressive, concentration dependent
lowering of basal and maximal transport rates as the glucose level was raised
to 20 mM. Thisdata indicated that insulin-responsiveness can be impaired by
at least two mechanisms, one glucose dependent and the other glucose-
independent.
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Finally, insulin can heterologously inhibit dexamethasone's effect on glucose
transport at both early and late phases of desensitisation. Dexamethasone did
not alter cell surface insulin binding and therefore the decrease in insulin
sensitivity and maximal insulin responsiveness were due to effects distal to
receptor binding. These studies reinforce the fact that the glucose transport
system is subject to complex hormonal regulation.
We therefore set out to examine the effects of dexamethasone (as a control)
and sex steroids, in the form of oestrogens, on insulin-stimulated glucose
transport in 3T3-Ll adipocytes. Figure 5.3 shows that the chronic inhibition
of insulin-stimulated glucose transport by dexamethasone is dose dependent
with an ICSOof approximately 15 nM. These results are in good agreement
with the data of Garvey et al. (1989).
Oestriol (E3) treatment of 3T3-L1 adipocytes for 48 h was observed to result in
a profound decrease in cute insulin-stimulated glucose transport with an ICso
similar to that of dexarnethasor e (figure SA). In contrast, incubation of
adipocytes with oestradiol (E2) for 48 h induced only a partial reduction in
subsequent acute insulin-stimulated glucose transport. Furthermore, this
inhibition was only observed at concentrations of greater than 30 nM (figure
5.5). Under these conditions, we observed a rightward-shift in the dose
response curve for insulin-stimulated glucose transport (ICSO3 nM Vs ",20
nM) (data not shown). Prolonged treatment with oestrogen (El) (48 hours)
also resulted in decreased insulin-stimulated glucose transport (ICSO 22 nM)
(figure 5.6).
As, after steroid treatment, these cells displayed a decrease in the uptake of
PH] 2-deoxy-D-glucose it was decided to examine the level of GLUT-4expressed
in sub-cellular fractions of the 3T3-Ll adipocytes.
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Figure 5.3
Inhibition of insulin stimulated 2-deoxy-O-glucose uptake by
dexamethasone.
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Figure 5.3
Inhibition of insulin stimulated 2-deoxy-O-glucose uptake
by dexamethasone.
3T3-L1 adipocytes, at least 8 days post-differentiation, were treated with
dexamethasone, at the concentrations shown, 48 hours prior assaying the
cells for insulin-stimulated 2-deoxy-O-glucose uptake. This assay was carried
out as in section 2.3.7 of this thesis on 3 occasions.
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Figure 5.4
Inhibition of insulin-stimulated glucose transport by oestriol (E3)
in 3T3-L1 adipocytes.
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Figure 5.4
Inhibition of insulin stimulated 2-deoxy-O-glucose uptake
by oestriol (E3).
3T3-L1adipocytes, at least 8 days post-differentiation, were treated with E3, at
the concentrations shown, 48 hours prior assaying the cells for insulin-
stimulated 2-deoxy-D-glucose uptake. This assay was carried out as in section
2.3.7 of this thesis on 3 occasions.
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Figure 5.5
Inhibition of insulin-stimulated glucose transport by oestradiol
(E2) in 3T3-L1 adipocytes.
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Figure 5.5
Inhibition of insulin stimulated 2-deoxy-D-glucose uptake
by oestradiol (E2).
3T3-Ll adipocytes, at least 8 days post-differentiation, were treated with E2, at
the concentrations shown, 48 hours prior assaying the cells for insulin-
stimulated 2-deoxy-D-glucose uptake. This assay was carried out as in section
2.3.7 of this thesis on 3 occasions.
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Figure 5.6
Inhibition of insulin-stimulated glucose transport by oestrogen
(El) in 3T3-L1 adipocytes.
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Figure 5.6
Inhibition of insulin stimulated 2-deoxy-D-glucose uptake
by oestrogen (El).
3T3-L1adipocytes, at least 8 days post-differentiation, were treated with El, at
the concentrations shown, 48 hours prior assaying the cells for insulin-
stimulated 2-deoxy-D-glucose uptake. This assay was carried out as in section
2.3.7 of this thesis on 3 occasions.
171
Such an analysis would be expected to reveal any decreases in total cellular
GLUT-4levels, or illustrate alterations in the subcellular distribution of GLVT-
4. Figure 5.7 shows a representative immunoblot of GLUT-4 present in the
low density microsomes (LDMs) of cells treated with either ethanol (vehicle
control) or sex-steroids as indicated. The bands were then cut out of the
nitrocellulose and v-counted as described in section 2.6 of this thesis to allow
quantification of the levels of GLUT-4 protein. Figure 5.8 illustrates that
there is no decrease in GLVT-4in the LDMspost steroid treatment.
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Figure 5.7
An immunoblot illustrating the level of GLUT-4 present in
low density microsomes of 3T3-Ll adipocytes.
Shown is a representative immunoblot of the 3T3-Ll adipocyte low density
microsomes (LDM) fraction probed with antibodies against GLUT-4 post
treament with the steroid indicated in the x-axis legend. 25!1gof membrane
protein were loaded on each lane. In this representative experiment 30nM El,
E2 and E3 were added for 48 hours. Eth represents ethanol as a vehicle control.
Quantification of the data was as outlined and collated data is shown in figure
5.8.
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Figure 5.8
Relative level of GLUT-4 in low density microsomes of treated 3T3-
L1 adipocytes.
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Figure 5.8
Relative level of GLUT-4 in low density microsomes of
treated 3T3-L1 adipocytes.
QJlantification of immunoblot data from figure 5.7.
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5.5 Discussion
The induction of insulin resistance in 3T3-L1adipocytes, by oestrogen and
derivatives has generated a model which may be utilised to examine the
aetiology of insulin resistance, such as that observed in post-menopausal
women on hormone replacement therapy.
Other conditions have been shown to induce insulin resistance in 3T3-L1
adipocytes, In a study by Pilch et al. (1997), 3T3-Ll adipocytes were treated
with tumour necrosis factor-a (TNF-a). Previous studies had identified TNF-a
as being associated with profound insulin resistance in adipocytes, and TNF-a
also been implicated in the development of insulin resistance associated with
obesity and non-insulin dependent diabetes mellitus [Stephens et al. (1991)].
Pilch and co-workers demonstrated that a prolonged exposure of 3T3-L1
adipocytes to TNF-a(up to 96 h) resulted in the reduction in the levels of IRS-
1 and GLUT-4mRNA,and protein. Furthermore, the level of the insulin
receptor is also reduced by between 30% and 50%. Interestingly, the
remaining proteins are biochemically indistinguishable from those in
untreated adipocytes. Despite the reduction in both GLUT-4and other
proteins, some degree of residual insulin-stimulated glucose transport and
GLUT-4translocation was still observed in TNF-a treated adipocytes. Pilch
proposes that the reason for the observed insulin resistance is the reduction
in the requisite proteins involved in insulin action. The insulin resistance
caused by oestrogen treatment obviously occurs via an alternative
mechanism as we see no reduction in the level of either GLUT-4or PI3 kinase
protein levels in comparison to untreated cells.
As has been stated many times during the course of this thesis, skeletal
muscle is the most important insulin-sensitive system, accounting for
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approximately 95% of total glucose disposal. Recently a study has been
carried out looking at the mechanisms of glucocorticoid-induced insulin
resistance in rat soleus muscle [Dimitriadis et al (1997)]. Male Wistar rats
were injected with O.5mg/day dexamethasone for 5 days prior to sacrifice.
The soleus muscle was dissected and experiments demonstrated that
dexamethasone decreased 3-0methylglucose transport, 2 deoxy-D-glucose
phosphorylation, glycogen synthesis and glucose oxidation in response to
insulin. However, the decrease in glucose transport is the not result of a
decrease in the total GLUT-4content as this remained unaltered in response to
dexamethasone treatment. However, subsequent subcellular fractionation
analysis showed that the insulin-stimulated increase in GLUT-4at the plasma
membrane was significantly diminished in dexamethasone treated animals
compared to controls. These results suggest that glucocorticoid excess causes
insulin resistance in skeletal muscle by directly inhibiting the translocation
of the glucose transporter GLUT-4 to the plasma membrane following
stimulation by insulin. It is possible that a similar mechanistic basis underlies
the inability of insulin to stimulate glucose transport in adipocytes treated
with steroids. The results obtained in these experiments highlight the
limitation of using 3T3-Ll adipocytes, These cell can only be used 8-13 days
post differentiation. It would be advantageous to study what effect the
administering much lower doses of steroid for a longer period of time would
have upon insulin-stimulated glucose transport. Furthermore, longer-term
exposure to steroids at lower concentrations may induce the same responses
observed in this chapter, but with more physiological relevance.
177
5.6 Future work
As stated throughout this thesis, and depicted in figure 1.6, there are many
potential sites of insulin resistance, from the insulin receptor to mis-
targeting of GLUT-4.Studies aimed at addressing each of these potential sites
of lesion in the insulin-stimulated pathway of translocation would be useful.
However,due to time constraints, it was not possible to complete such studies.
Someof the experiments which could be undertaken are detailed below:
.It would be of interest to study the distribution of GLUT-4,after stimulation
by insulin in order to determine if GLUT-4is being translocated efficiently to
the plasma membrane.
•Similarly, translocation of GLUT-4 containing vesicles to the plasma
membrane but no subsequent fusion of these vesicles with the membrane
should also be considered.
• Immunoblotting for members of the insulin signalling pathway to
determine if one or more of these proteins are expressed at a lower level,
therefore accounting for the reduction in insulin-stimulated glucose
transport would be appropriate. Such proteins include PI-3 kinase, IRS-l and
c-AKT. Additionally, it is possible to assay for enzymes such as PI-3 kinase,
this information would be invaluable in determining if such proteins
function efficiently in treated adipocytes..
Another issue we would like to address is the exposure of lower concentration
of steroids for a longer period of time. At the moment the concentration of
oestrogen used is much higher than the physiological concentration used in
the contraceptive pill and HRT,and is also a pharmacological dose, rather
than a physiological one. Unfortunately, because cultured adipocytes have
an effective window of only 4 days during which steroid administration can
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be administered, it has not been possible to examine the effect of multiple
lower doses of steroid (for example). This situation would be a more accurate
reflection of the situation faced by patients on HRT.
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Chapter 6
Overview
180
Insulin is the main anabolic and anti-catabolic hormone in mammals. In
fulfilling this role, insulin induces large modification in carbohydrate, lipid
and protein metabolism in hepatic, muscle and adipose tissues. Insulin
resistance is said to occur whenever normal concentrations of insulin
produce a subnormal biological response. Most commonly associated with
insulin resistance is a decrease in glucose uptake, especially in adipose and
more importantly skeletal muscle. It is important to note that insulin
resistance may only involve one tissue within a mammal, with all other
tissues responding normally to insulin stimulation. Furthermore, insulin
resistance may affect pathways other than those of glucose uptake, such as
lipid or potassium uptake, or sodium retention, which are other important
actions of insulin.
Severe insulin resistance can lead to non-insulin dependent diabetes mellitus
(NIDDM)in individuals where both fasting and postprandial plasma glucose
levels are elevated. The fact the NIDDM,obesity and primary hypertension
often occur together in the clinical situation implies that there may be some
common factors in the underlying pathology of these conditions [Livingstone
et al., (1995)]. In general hypertensive subjects have a degree of insulin
resistance. Furthermore, the insulin resistance which accompanies
hypertension is distinct from the in obesity and NIDDMin that it only affects
glucose uptake and subsequent glycogen synthesis, and is limited to
peripheral, insulin-sensitive tissues. Most evidence suggests that insulin
resistance precedes hypertension, this strongly suggesting that metabolic
abnormalities contribute to the development of hypertension. Although
many theories have been postulated, the mechanism of this remains unclear
[Donnelly& Connell (1992)].
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This thesis attempted to examine the reduction in insulin-stimulated glucose
transport in the hypertensive Milan rat, and after identified a reduction in
GLUT-4 in the LDMs of skeletal muscle. This discovery may explain the
insulin resistance experienced by this rodent model. There may be additional
defects in the insulin receptor signalling pathway that also contribute to the
disease state in these animals. In contradiction to this the SHRSP rat strain
shows no reduction in GLUT-4levels in skeletal muscle or adipose tissue. This
rodent model of hypertension is thought to best mimic human essential
hypertension, therefore the results are not surprising, as a reduction in
GLUT-4 is not commonly found in insulin resistant, hypertensive patients.
An, as yet unidentified, alternative mechanism of insulin resistance produces
the disease state in these animals. Due to the constraints of time and more
importantly animal tissue we were unable to further elucidate the location of
this defect. It is our belief that the many enzymes involved in the insulin
receptor signalling pathway may be site of fruitful research in the
forthcoming years.
Finally, we decided to examine the role of steroid hormones on insulin
resistance in 3T3-Ll adipocytes, This was done based on the fact that women
on steroid treatment, either by means of the contraceptive pill, or on HRT,
became insulin resistant. Previous studies had shown that glucocorticoids
induce insulin resistance in this cell line. Indeed, after 48 hours of treatment
with oestrogen, or derivatives, the cells showed a reduction in insulin-
stimulated 2-deoxy-D-glucose uptake. This demonstrated that the cells had
become insulin resistant. Immunoblotting for GLUT-4 in sub-cellular
fractions of the cells showed that there was no reduction in GLUT-4 protein
levels. Once again the mechanism of this insulin resistance remains unclear.
Further work on the proteins involved in insulin receptor signalling may
again prove. In this case it is possible to measure the activity of PI-3 kinase, a
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key enzyme in the signal transduction process. Additionally, it may be
beneficial to determine the efficiency of GLUT-4 translocation from the
intracellular membranes to the cell surface. A defect in the translocationary
machinery, may also result in the reduction of insulin-stimulated glucose
uptake.
It is clear from this study that insulin resistance is condition that arises in
many different and unrelated disease states. Although the mechanism of
insulin resistance is known in some cases, it is apparent that there are a
variety of mechanisms that can induce insulin resistance, affecting many
different proteins, at the level of both transcription and translation.
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